Data / Research funding / Malaria
Malaria: 641 NIH awards ($758.7M) to 178 organizations
641 NIH awards ($758.7M) in the NIH spending category Malaria, to 178 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 641 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| University of Washington Vaccine and Treatment Evaluation Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,173,751 | December 11, 2019 | November 30, 2026 | WALD, ANNA | reporter.nih.gov |
| Kaiser Washington Vaccine and Treatment Evaluation Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $14,173,633 | December 11, 2019 | November 30, 2026 | JACKSON, LISA A | reporter.nih.gov |
| Realizing Effectiveness Across Continents with Hydroxyurea(REACH): A Phase I/II Pilot Study of Hyroxyurea for Children with Sickle Cell Anemia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $6,498,374 | August 1, 2017 | July 31, 2027 | WARE, RUSSELL E | reporter.nih.gov |
| Biologically informed design of CD8+ T cell-dependent pre-erythrocytic stage malaria vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,330,175 | February 4, 2021 | January 31, 2026 | KAPPE, STEFAN HI | reporter.nih.gov |
| Enhancing immunity to malaria in young children with effective chemoprevention | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,263,495 | July 1, 2025 | June 30, 2027 | JAGANNATHAN, PRASANNA | reporter.nih.gov |
| Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasite vaccines and use of a unique adjuvant. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,933,702 | April 8, 2021 | March 31, 2027 | SIM, B. KIM LEE | reporter.nih.gov |
| Computational models of naturally acquired immunity to falciparum malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,666,873 | April 1, 2020 | March 31, 2026 | GREENHOUSE, BRYAN R | reporter.nih.gov |
| Improving Neonatal health Through Rapid malaria testing in Early Pregnancy with high-sensitivity Diagnostics (INTREPiD) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $5,664,388 | April 1, 2022 | March 31, 2027 | TAYLOR, STEVE MYER | reporter.nih.gov |
| DON in Pediatric Cerebral Malaria: A Phase I / II Dose-Escalation Safety Study | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,567,850 | June 1, 2025 | May 31, 2027 | POSTELS, DOUGLAS | reporter.nih.gov |
| Focal mass drug administration (fMDA) to reduce Plasmodium vivax transmission, a pragmatic cluster randomized controlled trial in Peru | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $5,036,878 | June 1, 2025 | May 31, 2027 | HSIANG, MICHELLE SANG | reporter.nih.gov |
| Accelerating discovery of an efficacious Plasmodium vivax multivalent multi-stage vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,835,728 | December 1, 2020 | November 30, 2026 | ADAMS, JOHN H | reporter.nih.gov |
| Optimal chemopreventive regimens to prevent malaria and improve birth outcomes in Uganda | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,809,096 | April 15, 2020 | March 31, 2026 | DORSEY, MATTHEW G | reporter.nih.gov |
| Development of Non-Human Primate Models to Assess Immunological Mechanisms and Antigenic Targets of Protective Sporozoite (SPZ) Vaccines and Establish Superior Efficacy of Next Generation SPZ vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,717,265 | April 1, 2021 | March 31, 2027 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| Mechanisms of innate immune dysfunction in SIV/malaria co-infection in pregnancy | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $4,672,308 | September 24, 2021 | July 31, 2026 | MANUZAK, JENNIFER | reporter.nih.gov |
| Long-term health and socioeconomic impact of interventions targeting low-density malaria infection (LMI) among children in Tanzaniav | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,537,676 | April 15, 2022 | March 31, 2027 | HSIANG, MICHELLE SANG | reporter.nih.gov |
| Structural Analysis and Inhibitor Optimization of Cryptosporidium n-myristoyltransferase for Drug Discovery | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,163,372 | November 15, 2020 | October 31, 2026 | STAKER, BART LEE | reporter.nih.gov |
| Integrating human and non-human primate data to understand the acquisition of pre-erythrocytic immunity in the face of previous malaria exposure | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,114,200 | February 10, 2022 | January 31, 2027 | WILDER, BRANDON KEITH | reporter.nih.gov |
| Development of an oral liver-targeted prime-and-trap malaria vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,104,491 | December 1, 2020 | November 30, 2026 | MURPHY, SEAN C | reporter.nih.gov |
| Mosquito SAMSP1 and SAMSP2 influence the initial stage of Plasmodium infection of mice | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,052,693 | April 14, 2021 | March 31, 2027 | FIKRIG, EROL | reporter.nih.gov |
| Defining functional humoral correlates of immunity to guide vaccine design | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,023,233 | November 24, 2020 | October 31, 2025 | BATISTA, FACUNDO DAMIAN | reporter.nih.gov |
| A systems immunology approach to evaluate malaria vaccine performance in endemic regions of Kenya | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,921,000 | February 1, 2022 | January 31, 2027 | MOORMANN, ANN M | reporter.nih.gov |
| Selective Plasmodium proteasome inhibitors as novel multi-stage antimalarials | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,856,328 | September 1, 2019 | August 31, 2029 | LIN, GANG | reporter.nih.gov |
| Optimization of novel phenotypic screening hits for treatment of Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,843,960 | April 1, 2021 | March 31, 2027 | PHILLIPS, MARGARET A. | reporter.nih.gov |
| Lead Optimization of DHODH Inhibitors for Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,721,559 | January 1, 2013 | June 30, 2028 | PHILLIPS, MARGARET A. | reporter.nih.gov |
| Malaria across borders: Measuring imported infections and contributions to local transmission in Uganda and Zimbabwe | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,679,817 | June 16, 2021 | May 31, 2027 | RODRÍGUEZ-BARRAQUER, ISABEL | reporter.nih.gov |
| Severe Malaria And Risk to The Brain (SMART Brain) | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,674,964 | April 15, 2008 | January 31, 2029 | JOHN, CHANDY C. | reporter.nih.gov |
| Optimizing the dose of tafenoquine for the radical cure of Plasmodium vivax malaria in Southeast Asia | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,588,034 | September 8, 2023 | August 31, 2028 | CHU, CINDY S | reporter.nih.gov |
| Inducing durable, protective immune memory against malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,488,192 | January 16, 2019 | December 31, 2023 | KAPPE, STEFAN HI | reporter.nih.gov |
| Mechanisms of varied sensitivity of P. falciparum field isolates to the antimalarial drug pipeline | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,469,861 | July 1, 2025 | June 30, 2028 | ROSENTHAL, PHILIP JON | reporter.nih.gov |
| Evaluating the role of P53 pathways in malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,424,681 | February 1, 2021 | January 31, 2027 | TRAN, TUAN MANH | reporter.nih.gov |
| Chemogenomic Profiling of Plasmodium Falciparum Responses and Resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,402,300 | February 10, 2015 | June 30, 2027 | ADAMS, JOHN H | reporter.nih.gov |
| Uncovering the parasite and host determinants of Plasmodium vivax hypnozoite formation and development using single cell sequencing and human liver-chimeric mice | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,399,010 | February 7, 2022 | January 31, 2027 | VAUGHAN, ASHLEY M | reporter.nih.gov |
| Structure and function of the Plasmodium myosin XIV-actin glideosome. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,384,780 | May 11, 2017 | June 30, 2027 | TRYBUS, KATHLEEN M | reporter.nih.gov |
| Improving Response to Malaria Outbreaks in Amazon-Basin Countries | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,375,825 | September 1, 2025 | August 31, 2026 | PAN, WILLIAM KUANG-YAO | reporter.nih.gov |
| Innate Immune Activation in Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,341,812 | September 24, 2009 | February 28, 2025 | GOLENBOCK, DOUGLAS T | reporter.nih.gov |
| Elucidating the role of TSR glycosylation in Plasmodium parasites | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,339,688 | June 1, 2020 | May 31, 2026 | SWEARINGEN, KRISTIAN EDWARD | reporter.nih.gov |
| Second-Generation Novel Liver Stage Active Antimalarials | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,320,110 | April 1, 2021 | March 31, 2027 | KELLY, JANE X | reporter.nih.gov |
| Defining the resistome in P. falciparum: evolution and mechanism | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,309,597 | November 2, 2022 | October 31, 2027 | WINZELER, ELIZABETH A | reporter.nih.gov |
| A structured transcriptional switching network that coordinates antigenic variation by malaria parasites | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,290,341 | September 22, 2021 | August 31, 2027 | DEITSCH, KIRK W | reporter.nih.gov |
| Malaria parasite determinants of host cell tropism | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,286,067 | July 1, 2022 | June 30, 2027 | DURAISINGH, MANOJ T | reporter.nih.gov |
| Once Bitten: Acquisition of Malaria Adaptive Immunity (OBAMA - Immunity) | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,285,014 | July 1, 2025 | June 30, 2028 | PRUDHOMMEOMEARA, WENDY | reporter.nih.gov |
| Treating Brain Swelling in Pediatric Cerebral Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,271,417 | December 12, 2016 | November 30, 2023 | TAYLOR, TERRIE ELLEN | reporter.nih.gov |
| Pathogenic low affinity CD8 T cells in malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,264,359 | September 17, 2021 | August 31, 2026 | LAMB, TRACEY JANE | reporter.nih.gov |
| Spatial Targeting and Adaptive Vector Control for Residual Transmission and Malaria Elimination in Urban African Settings | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,239,370 | June 9, 2021 | May 31, 2027 | SMITH, DAVID L. | reporter.nih.gov |
| Mechanisms and consequences of extrafollicular B cell activation during malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,235,595 | September 24, 2021 | August 31, 2027 | BUTLER, NOAH SULLIVAN | reporter.nih.gov |
| Drivers of strain-specific and strain-transcendent antimalarial immunity in childhood | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,209,021 | June 17, 2020 | May 31, 2026 | GREENHOUSE, BRYAN R | reporter.nih.gov |
| Impact of gene-drive systems for population modification on malaria vector mosquitoes | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,173,474 | June 9, 2023 | May 31, 2026 | JAMES, ANTHONY A. | reporter.nih.gov |
| The role of γδ T cells in fetal and infant immune defense against malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,151,506 | March 15, 2011 | May 31, 2027 | FEENEY, MARGARET E | reporter.nih.gov |
| Plasmodium Protein Kinase Focused Antimalarials Discovery | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,144,589 | July 11, 2022 | June 30, 2027 | CHAKRABARTI, DEBOPAM | reporter.nih.gov |
| Redefining thermal suitability for urban malaria transmission in the context of humidity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,108,969 | September 14, 2020 | August 31, 2027 | MURDOCK, COURTNEY | reporter.nih.gov |
| Novel Therapeutics to Target Parasite Cytochrome bc1 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,077,845 | July 15, 2012 | June 30, 2027 | RISCOE, MICHAEL KEVIN | reporter.nih.gov |
| Molecular basis of antimalarial drug resistance in Plasmodium vivax | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,064,807 | March 18, 2022 | February 28, 2027 | DURAISINGH, MANOJ T | reporter.nih.gov |
| Systems biological assessment of vaccination-induced protective immunity in African children | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,037,984 | February 1, 2022 | January 31, 2027 | PULENDRAN, BALI | reporter.nih.gov |
| Innate Immune Mechanisms Governing Subclinical Malaria in Children | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,030,131 | September 1, 2022 | August 31, 2026 | KAZURA, JAMES WALTER | reporter.nih.gov |
| Novel Antimalarials from Fungi | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,025,049 | May 18, 2020 | April 30, 2026 | CHAKRABARTI, DEBOPAM | reporter.nih.gov |
| A Unique Automated Bioreactor for Rearing Aseptic Mosquitoes from Larvae to Adults to Support Manufacture of Sanaria PfSPZ Products | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,000,000 | July 18, 2018 | March 31, 2025 | BILLINGSLEY, PETER F. | reporter.nih.gov |
| Long Lasting Organic Semiochemical Formulation to Effectively Manage Blood Sucking Diptera. | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $3,000,000 | July 12, 2017 | January 31, 2026 | MAFRA-NETO, AGENOR | reporter.nih.gov |
| Cofactor metabolism and mitochondrial function in malaria parasites | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,998,772 | August 18, 2023 | July 31, 2027 | PRIGGE, SEAN TAYLOR | reporter.nih.gov |
| A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stage | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,998,001 | April 21, 2020 | March 31, 2027 | SIM, B. KIM LEE | reporter.nih.gov |
| Progressing PfSPZ vaccines for malaria to licensure and commercialization | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,994,338 | April 14, 2023 | March 31, 2027 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| Functional investigation of a novel and essential subcellular compartment in Plasmodium falciparum transmission stage parasites | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,972,178 | March 4, 2022 | February 28, 2027 | DVORIN, JEFFREY D | reporter.nih.gov |
| Optimization of antimalarials targeting multiple life stages of the parasite | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,967,032 | August 4, 2021 | July 31, 2027 | CARLIER, PAUL R | reporter.nih.gov |
| Advancing Fast-acting Antimalarials that Disrupt Na+ Homeostasis in Parasites | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,964,364 | August 12, 2020 | July 31, 2026 | VAIDYA, AKHIL B | reporter.nih.gov |
| Pharmacological insights into antimalarial exposure, clinical outcomes, and drug resistance in Africa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,963,157 | February 10, 2015 | April 30, 2026 | ROSENTHAL, PHILIP JON | reporter.nih.gov |
| Artemisinin Resistance in Africa: its emergence and evolution in Rwanda | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,954,668 | August 5, 2021 | July 31, 2025 | BAILEY, JEFFREY A. | reporter.nih.gov |
| Determining the interactions between mosquito oogenesis and Plasmodium falciparum survival and transmission | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,950,744 | June 11, 2020 | May 9, 2025 | CATTERUCCIA, FLAMINIA | reporter.nih.gov |
| A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with an attenuated, live sporozoite malaria vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,935,817 | July 1, 2016 | June 30, 2025 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| A universal malaria T cell vaccine based on HLA-E presentation | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,934,908 | May 20, 2022 | April 30, 2027 | WILDER, BRANDON KEITH | reporter.nih.gov |
| Phase II STTR development of an intranasal/oral Spirulina-based PfCSP malaria vaccine. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,925,300 | May 17, 2018 | June 30, 2025 | KHUONG, NHI | reporter.nih.gov |
| Automating mosquito microdissection for a malaria PfSPZ vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,924,306 | June 20, 2017 | April 30, 2025 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| Genomic and geospatial analyses of malaria parasite migration to inform elimination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,915,635 | March 1, 2020 | February 28, 2026 | HARRISON, SHANNON TAKALA | reporter.nih.gov |
| Leveraging PfCRT Structure to Discern Function and Predict Emergence of Drug-Resistant Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,908,665 | July 1, 2019 | November 30, 2029 | MANCIA, FILIPPO | reporter.nih.gov |
| The synergistic contributions of EBV and malaria to the etiology of Burkitt lymphoma | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,895,508 | December 12, 2019 | January 31, 2025 | SAMAYOA REYES, GABRIELA M | reporter.nih.gov |
| PreQuine Platform. A novel point of care device for the diagnosis andmonitoring of Glucose-6-Phosphate Dehydrogenase (G6PD) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,893,164 | February 8, 2017 | August 31, 2025 | HARPER, ROBERT | reporter.nih.gov |
| Malaria transmission blocking through mosquito contact with treated surfaces | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,877,675 | February 4, 2020 | January 31, 2026 | CATTERUCCIA, FLAMINIA | reporter.nih.gov |
| Dual artemisinin action combats resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,862,998 | March 18, 2021 | February 28, 2027 | SULLIVAN, DAVID JOSEPH | reporter.nih.gov |
| Gut microbiota and human malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,860,358 | July 1, 2020 | June 30, 2026 | SCHMIDT, NATHAN | reporter.nih.gov |
| Defining targets of protective immunity to vivax malaria using human monoclonal antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,825,320 | March 24, 2020 | February 28, 2026 | KING, CHRISTOPHER L | reporter.nih.gov |
| Relapsing malaria in Africa: mechanisms for persistence amid falciparum decline | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,825,021 | July 25, 2022 | June 30, 2027 | JULIANO, JONATHAN J | reporter.nih.gov |
| Importation and transmission of malaria in Zanzibar: a case study for elimination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,816,019 | August 1, 2021 | July 31, 2025 | JULIANO, JONATHAN J | reporter.nih.gov |
| Mechanisms of endothelial dysfunction in cerebral malaria and barrier restorative pathways | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,808,572 | September 23, 2020 | August 31, 2025 | SMITH, JOSEPH D | reporter.nih.gov |
| Accelerating Malaria Vaccines with a Custom Preclinical Humanized Mouse Model Platform | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,803,324 | March 1, 2022 | February 28, 2027 | BATISTA, FACUNDO DAMIAN | reporter.nih.gov |
| Developing a multi-component vaccine harnessing potent antibody and cellular responses against the blood-stage of Plasmodium falciparum | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,802,178 | May 1, 2022 | April 30, 2027 | SRINIVASAN, PRAKASH | reporter.nih.gov |
| After the flood: Optimal strategies to prevent malaria epidemics caused by severe flooding | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,800,889 | September 1, 2025 | August 31, 2028 | BOYCE, ROSS MATHEW | reporter.nih.gov |
| Discovery of long-acting, chemoprotective antimalarial compounds | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,791,259 | March 25, 2020 | February 28, 2026 | WINZELER, ELIZABETH A | reporter.nih.gov |
| Evaluating the Functional Impact of Genetic Diversity on Malaria Vaccine Candidates | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,788,646 | August 1, 2025 | July 31, 2027 | BEI, AMY KRISTINE | reporter.nih.gov |
| Mapping Drug Resistance Genes in Plasmodium falciparum | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,782,422 | September 1, 2000 | November 30, 2027 | ANDERSON, TIM J | reporter.nih.gov |
| Collective Responses to Malaria Vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,779,001 | February 9, 2022 | January 31, 2027 | STUART, KENNETH D | reporter.nih.gov |
| Host and parasite factors influencing P. vivax RBC invasion and asexual development | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,748,338 | June 1, 2025 | May 31, 2027 | SERRE, DAVID | reporter.nih.gov |
| Harnessing the Malarial Immunity Omics Landscape in Vaccinated and Unvaccinated Children for Improved Therapeutic Strategies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,743,704 | July 1, 2025 | June 30, 2029 | PERKINS, DOUGLAS JAY | reporter.nih.gov |
| Proline homeostasis: a novel mediator of drug tolerance in Plasmodium falciparum | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,742,796 | April 1, 2020 | March 31, 2025 | MAZITSCHEK, RALPH | reporter.nih.gov |
| Defining conserved epitopes on polymorphic malaria antigens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,726,813 | February 19, 2021 | January 31, 2027 | BUNNIK, EVELIEN MARGARETHA | reporter.nih.gov |
| COVID Transmission and Morbidity in Malawi (COVID-TMM) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,666,340 | April 1, 2025 | March 31, 2027 | VALIM, CLARISSA | reporter.nih.gov |
| Molecular pathways affected by drugs that disrupt Na+ and lipid homeostasis in malaria parasites | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,652,142 | May 5, 2017 | December 31, 2027 | VAIDYA, AKHIL B | reporter.nih.gov |
| Lead optimization and target identification of drugs targeting hypnozoites | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,647,674 | August 7, 2020 | July 31, 2025 | KYLE, DENNIS E | reporter.nih.gov |
| Resistance of Malaria Parasites to Artemisinin-Based Combination Therapies in Uganda | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,627,211 | August 1, 2008 | August 31, 2025 | ROSENTHAL, PHILIP JON | reporter.nih.gov |
| Baseline host and environmental factors that impact pre-erythrocytic malaria vaccine (hypo)responsiveness in endemic regions | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,600,040 | March 8, 2022 | February 28, 2027 | YAZDANBAKHSH, MARIA | reporter.nih.gov |
| Global Research Endeavors to Advance Treatment of Neurological Disorders in Africa (GREAT Neurology) | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,561,391 | May 1, 2021 | April 30, 2029 | BIRBECK, GRETCHEN L. | reporter.nih.gov |
| Defining the Role of PfCRT and PfMDR1 as Pleiotropic Mediators of Plasmodium falciparum Multidrug Resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,538,591 | August 1, 2001 | January 31, 2028 | FIDOCK, DAVID A | reporter.nih.gov |
| Novel Multiple-Stage Active Antimalarials | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,520,964 | June 14, 2019 | August 31, 2030 | KANCHARLA, PAPIREDDY | reporter.nih.gov |
| A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $2,501,040 | September 30, 2023 | September 29, 2028 | TSUJI, MORIYA | reporter.nih.gov |
| Malaria associated pathogenesis of chronic kidney disease (MAP-CKD) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,470,944 | June 1, 2025 | May 31, 2027 | CONROY, ANDREA L. | reporter.nih.gov |
| Development of a pre-erythrocytic P. vivax vaccine to prevent clinical relapse | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,467,626 | January 1, 2019 | December 31, 2023 | SATHER, D. NOAH | reporter.nih.gov |
| Impairment of anti-Plasmodium T cell memory by type I Interferon Signaling | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,456,734 | June 1, 2023 | May 31, 2028 | MINKAH, NANA KWAKU | reporter.nih.gov |
| Immunity to Liver-stage malaria | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,414,340 | January 12, 2022 | January 14, 2025 | HARTY, JOHN T | reporter.nih.gov |
| Epidemiology and determinants of emerging artemisinin-resistant malaria in Ethiopia | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,413,258 | June 9, 2023 | May 31, 2028 | PARR, JONATHAN BOYD | reporter.nih.gov |
| Impact of malaria on shaping immunity to EBV in the etiology of Burkitt lymphoma | NIH | National Cancer Institute | 2021 to 2024 | $2,374,490 | July 10, 2014 | June 30, 2025 | MOORMANN, ANN M | reporter.nih.gov |
| Liver resident memory for malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,368,344 | November 23, 2018 | October 31, 2024 | MURPHY, SEAN C | reporter.nih.gov |
| Maturation of human humoral immunity through repeat malaria challenges | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,367,571 | May 24, 2023 | April 30, 2028 | WILLIAMSON, KIM C | reporter.nih.gov |
| Rigorous Assessment of P. vivax Relapses and Primaquine Efficacy for Radical Cure | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,362,550 | July 17, 2020 | June 30, 2026 | SERRE, DAVID | reporter.nih.gov |
| Parasite and host cell factors involved in the formation and persistence of Plasmodium vivax hypnozoites | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,358,624 | February 9, 2023 | January 31, 2028 | KAPPE, STEFAN HI | reporter.nih.gov |
| Hijacking Plasmodium ubiquitin-proteasome system to defeat drug resistance | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,334,364 | July 1, 2023 | June 30, 2028 | LIN, GANG | reporter.nih.gov |
| Elucidating the functions of red blood cell factors in malaria parasite invasion | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $2,314,537 | July 1, 2023 | June 30, 2028 | EGAN, ELIZABETH S. | reporter.nih.gov |
| Surveillance to track and characterize antimalarial resistance trends in Ugandan Plasmodium falciparum parasites (STARTUP) | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,293,828 | December 20, 2022 | November 30, 2025 | CONRAD, MELISSA D | reporter.nih.gov |
| Development of next-generation gene drive technologies for Anopheles population engineering | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,276,593 | June 1, 2021 | May 31, 2026 | BIER, ETHAN | reporter.nih.gov |
| A modular platform for infectious disease surveillance at point-of-need. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,274,286 | August 7, 2020 | August 31, 2025 | FISHER, JAY KENNETH | reporter.nih.gov |
| Defining P. falciparum resistance to artemisinin-based combination therapies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,262,645 | August 1, 2014 | February 28, 2027 | FIDOCK, DAVID A | reporter.nih.gov |
| CD8 T cell mediated disruption of Blood Brain Barrier Tight Junctions | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,226,916 | July 1, 2017 | February 28, 2030 | JOHNSON, AARON J | reporter.nih.gov |
| MEP pathway resistance in Plasmodium falciparum | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,223,785 | December 1, 2012 | March 31, 2028 | ODOM JOHN, AUDREY RAGAN | reporter.nih.gov |
| Biogenic amines, malaria and manipulation of mosquito physiology and behavior. | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,184,819 | August 8, 2022 | July 31, 2027 | LUCKHART, SHIRLEY | reporter.nih.gov |
| Defining the mechanism of coma in cerebral malaria | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,123,692 | July 8, 2022 | June 30, 2027 | DAILY, JOHANNA PATRICIA | reporter.nih.gov |
| Multi-Omics Characterization of Plasmodium Vivax Hypnozoites | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,118,231 | December 22, 2022 | November 30, 2027 | SERRE, DAVID | reporter.nih.gov |
| Orally Bioavailable 4(1H)-Quinolones with Multi-Stage Antimalarial Activity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,114,325 | April 11, 2019 | March 31, 2025 | MANETSCH, ROMAN | reporter.nih.gov |
| Genome-wide sieve analysis and immunological validation to identify targets of protective efficacy in field trials of a whole-organism malaria vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,110,841 | January 15, 2019 | December 31, 2024 | CARNEIRO DA SILVA, JOANA | reporter.nih.gov |
| The role of natural killer cells and antibodies in protection from malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,108,688 | March 25, 2020 | February 28, 2026 | HART, GEOFFREY T | reporter.nih.gov |
| Statistical Methods for Efficacy Trials of Vaccines and Monoclonal Antibodies Against Genetically-Diverse Pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,067,031 | April 1, 2003 | June 30, 2029 | GILBERT, PETER B. | reporter.nih.gov |
| Epitope-Based CSP Vaccines Optimized to Achieve Long-Term Sterile Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,065,107 | August 23, 2023 | July 31, 2027 | MILICH, DAVID R. | reporter.nih.gov |
| Plasmodium falciparum gametocytogenesis in vitro and in vivo | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,054,301 | January 8, 2020 | December 31, 2025 | WILLIAMSON, KIM C | reporter.nih.gov |
| The Function of Antimalarial Drug Resistance Proteins | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,016,655 | June 15, 2003 | October 31, 2026 | ROEPE, PAUL D. | reporter.nih.gov |
| The evolution of copy number variations in the AT-rich Plasmodium genome | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,000,646 | April 1, 2021 | March 31, 2027 | GULER, JENNIFER LYNN | reporter.nih.gov |
| Recombinant Outer Membrane Vesicles as a Novel Adjuvant for a Malaria Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,999,755 | December 8, 2023 | November 30, 2026 | LOCHER, CHRISTOPHER | reporter.nih.gov |
| Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,995,482 | April 21, 2016 | July 31, 2027 | CHAKRAVARTY, SUMANA | reporter.nih.gov |
| Malarial retinopathy screening system for improved diagnosis of cerebral malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,992,098 | May 6, 2021 | April 30, 2024 | JOSHI, VINAYAK S | reporter.nih.gov |
| PfSPZ Vaccine for Malaria: Towards a Successful Biologics License Application and Commercialization | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,973,577 | February 15, 2004 | June 30, 2023 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| Identifying functional antibody responses that protect against malaria in children | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,938,902 | August 1, 2025 | July 31, 2027 | SEYDEL, KARL BOYNTON | reporter.nih.gov |
| Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,938,759 | April 21, 2016 | May 31, 2024 | CHAKRAVARTY, SUMANA | reporter.nih.gov |
| Perturbations of host cell signaling by a complex hepatotropic pathogen | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,938,593 | April 1, 2013 | January 31, 2028 | KAUSHANSKY, ALEXIS | reporter.nih.gov |
| Cryopreservation of Anopheles Embryos | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,928,928 | August 1, 2010 | January 31, 2024 | BILLINGSLEY, PETER F. | reporter.nih.gov |
| Dissecting the role of EBV and P. falciparum in endemic Burkitt lymphoma pathogenesis | NIH | National Cancer Institute | 2021 to 2023 | $1,923,862 | August 14, 2019 | January 31, 2025 | LUFTIG, MICAH A. | reporter.nih.gov |
| Defining the immunogenic landscape of early mosquito-stage P. falciparum to accelerate malaria transmission-blocking vaccine discovery | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,917,896 | July 5, 2024 | May 31, 2029 | SWEARINGEN, KRISTIAN EDWARD | reporter.nih.gov |
| In-Vitro Culture of Plasmodium falciparum Sporozoites for Malaria Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,912,715 | February 15, 2010 | May 31, 2025 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| Molecular mechanisms of schizogony in malaria parasites | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,900,856 | June 1, 2019 | May 31, 2025 | DVORIN, JEFFREY D | reporter.nih.gov |
| Natural Product Inspired Novel Antimalarials with Radical Cure Potential | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,900,470 | April 4, 2023 | March 31, 2028 | KANCHARLA, PAPIREDDY | reporter.nih.gov |
| Role of Translesional Polymerases in Genome Diversification of the Malaria Parasite | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,889,240 | June 10, 2019 | May 31, 2025 | KIRKMAN, LAURA | reporter.nih.gov |
| Type-I Interferons drive cell-autonomous immunity to malaria | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,887,500 | June 21, 2022 | May 31, 2027 | KURUP, SAM | reporter.nih.gov |
| How to starve a parasite: Manipulating CoA biosynthesis to control Plasmodium development in the mosquito | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,855,815 | April 14, 2023 | March 31, 2027 | RIEHLE, MICHAEL ALLEN | reporter.nih.gov |
| Primaquine metabolism and treatment of P. vivax in Madagascar | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,843,113 | January 1, 2020 | September 19, 2023 | ZIMMERMAN, PETER A. | reporter.nih.gov |
| Virus-like Particle based malaria vaccines targeting vulnerable epitopes in the circumsporozoite protein | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,841,511 | November 9, 2022 | October 31, 2027 | CHACKERIAN, BRYCE C | reporter.nih.gov |
| Genome-based diagnostics for mapping, monitoring and management of insecticide resistance in major African malaria vectors | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,808,286 | February 15, 2016 | May 31, 2027 | DONNELLY, MARTIN JAMES | reporter.nih.gov |
| Optimizing HIV-malaria treatment in a shifting treatment and resistance landscape in Africa | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 to 2025 | $1,796,782 | December 23, 2010 | June 30, 2029 | PARIKH, SUNIL | reporter.nih.gov |
| Extent, dynamics and mechanisms of Plasmodium vivax immune evasion caused by PvDBP gene amplification | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,777,806 | July 1, 2025 | June 30, 2028 | POPOVICI, JEAN | reporter.nih.gov |
| Immunological characterization of the P. vivax DBP | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,773,948 | August 1, 2006 | March 31, 2026 | ADAMS, JOHN H | reporter.nih.gov |
| Essential PK/PD relationships of antimalarial drugs | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,753,200 | February 1, 2012 | August 31, 2025 | SHAPIRO, THERESA A | reporter.nih.gov |
| The role of ascorbate in myelopoiesis and infection | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,753,030 | April 1, 2021 | July 31, 2026 | AGATHOCLEOUS, MICHALIS | reporter.nih.gov |
| DISCOVERY AND PRECLINICAL DEVELOPMENT OF EFFICACIOUS P. vivax PRE-ERYTHROCYTIC STAGE MALARIA VACCINES | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,745,498 | November 20, 2020 | October 31, 2023 | HERRERA VALENCIA, SOCRATES | reporter.nih.gov |
| Comprehensive characterization of the genetic factors and the host immune response associated to protection from clinical Plasmodium vivax malaria | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,744,699 | March 16, 2023 | February 29, 2028 | POPOVICI, JEAN | reporter.nih.gov |
| Once bitten: A longitudinal, observational study of successful malaria parasite transmission events between humans and mosquitos | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,739,571 | July 16, 2019 | June 30, 2024 | PRUDHOMMEOMEARA, WENDY | reporter.nih.gov |
| Mitochondrial Functions in Malaria Parasites | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,717,892 | July 1, 1989 | October 31, 2028 | VAIDYA, AKHIL B | reporter.nih.gov |
| ER-shaping proteins of Plasmodium | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,698,924 | June 1, 2021 | May 31, 2027 | BHANOT, PURNIMA | reporter.nih.gov |
| Harnessing the Unique Biogenesis of the Apicomplexan plastid organelle forAntimalarial Targets | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,687,625 | June 1, 2019 | May 31, 2025 | YEH, ELLEN | reporter.nih.gov |
| In vitro modeling of blood brain barrier dysfunction on a chip to elucidate the pathogenesis of cerebral malaria | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $1,675,237 | September 15, 2021 | August 31, 2023 | GOLIGHTLY, LINNIE | reporter.nih.gov |
| Regulation of Sexual Differentiation in Malaria Parasites | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,670,733 | June 12, 2019 | May 31, 2025 | KAFSACK, BJORN FELIX CAESAR | reporter.nih.gov |
| Exposure to Insecticides and Child Growth and Pubertal Development in a South African Population Exposed Through Indoor Residual Spraying | NIH | National Institute of Environmental Health Sciences | 2022 to 2025 | $1,663,772 | November 22, 2019 | October 31, 2026 | CHEVRIER, JONATHAN | reporter.nih.gov |
| Protective role of Neuregulin-1 against cerebral malaria-induced neuronal injury and behavioral sequelae | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2024 | $1,644,196 | January 1, 2022 | December 31, 2027 | STILES, JONATHAN K. | reporter.nih.gov |
| Rationally-Designed, Spontaneous-Particleized Pfs48/45 for a Multivalent Malaria Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,631,717 | May 20, 2020 | April 30, 2026 | LOVELL, JONATHAN F | reporter.nih.gov |
| Molecular basis of effector protein export in the malaria parasite Plasmodium falciparum | NIH | Office of the Director, National Institutes of Health | 2021 to 2024 | $1,620,000 | September 10, 2020 | August 31, 2025 | HO, CHI-MIN | reporter.nih.gov |
| Identification & Evaluation of Novel Malaria Anti-Gametocyte Transmission Blocking Vaccine Candidate Antigens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,594,902 | August 29, 2019 | July 31, 2025 | NIXON, CHRISTIAN PARCHER | reporter.nih.gov |
| Role of erythrocyte band 3 in malaria adhesion | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,591,509 | July 10, 1998 | July 31, 2025 | CHISHTI, ATHAR H. | reporter.nih.gov |
| Development of a Sustained Release Injectable Formulation for Long-Term Delivery of ELQs | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,582,032 | June 5, 2019 | May 31, 2024 | RISCOE, MICHAEL KEVIN | reporter.nih.gov |
| Latitudinal Landscape Genomics and Ecology of Anopheles Darlingi | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,580,362 | June 15, 2014 | August 31, 2025 | CONN, JAN E | reporter.nih.gov |
| Chemical Biology Strategies to Resolve Plasmodium Heat Shock Protein Function | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,568,340 | June 1, 2023 | May 31, 2028 | DERBYSHIRE, EMILY R | reporter.nih.gov |
| Exploring Wolbachia for malaria control | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,567,394 | February 1, 2024 | December 31, 2028 | XI, ZHIYONG | reporter.nih.gov |
| MOLECULAR ANALYSIS OF MALARIA MITOCHONDRIAL GENE REGULATION | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,564,992 | January 1, 2022 | December 31, 2026 | LANE, KRISTIN D | reporter.nih.gov |
| Targeting the compromised brain endothelial barrier function during cerebral malaria with AT2 receptor agonists | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,539,586 | December 15, 2019 | November 30, 2024 | RODRIGUEZ, ANA | reporter.nih.gov |
| Interactions between drug combinations and resistance acquisition risk for antimalarial ATP4 inhibitors | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,532,785 | June 7, 2024 | May 31, 2029 | GUY, RODNEY KIPLIN | reporter.nih.gov |
| Role of the Gut Microbiota in Shaping Severity of Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,532,068 | May 3, 2024 | April 30, 2029 | SCHMIDT, NATHAN | reporter.nih.gov |
| Evolutionary dynamics of zoonotic malaria | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,531,736 | January 25, 2023 | June 30, 2025 | GOLDBERG, AMY | reporter.nih.gov |
| Exploring the etiology of oxidative damage and cell death in placental malaria | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,525,553 | September 20, 2022 | July 31, 2027 | MOORE, JULIE M | reporter.nih.gov |
| Understanding and Targeting Host Processes Essential to Plasmodium Infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,516,224 | June 1, 2023 | May 31, 2028 | DERBYSHIRE, EMILY R | reporter.nih.gov |
| Mechanisms of compromised CD8 T cell responses to vaccination in malaria experienced hosts | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,507,165 | June 24, 2024 | April 30, 2029 | HARTY, JOHN T | reporter.nih.gov |
| SBIR Topic 109: Development of Monoclonal Antibody- Mediated Interventions to Combat Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $1,500,000 | September 18, 2024 | September 17, 2027 | MILLER, JACQUELINE | reporter.nih.gov |
| CRISPR-based Assay for Portable Tropical Infection Diagnosis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,499,763 | September 15, 2025 | September 14, 2028 | ZHUKOV, DMITRIY | reporter.nih.gov |
| Mobile Health Point-of-Care Diagnostics for Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,498,121 | July 19, 2021 | July 18, 2024 | PRICE, RHODA | reporter.nih.gov |
| Proteostasis in Plasmodium falciparum artemisinin resistance | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,493,872 | January 11, 2024 | November 30, 2028 | NG, CAROLINE L | reporter.nih.gov |
| Mechanisms of environmental sensing and responses by malaria parasites | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,491,706 | June 1, 2018 | May 31, 2024 | DEITSCH, KIRK W | reporter.nih.gov |
| Population Biology of African Malaria Vectors and Parasites | NIH | Fogarty International Center | 2021 to 2025 | $1,490,400 | September 29, 2000 | March 31, 2030 | YAN, GUIYUN | reporter.nih.gov |
| Elucidating the molecular basis of piperaquine resistance in Plasmodium falciparum | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,485,044 | February 1, 2016 | November 30, 2027 | FIDOCK, DAVID A | reporter.nih.gov |
| Data and analysis ecosystem for eukaryotic pathogen targeted sequencing | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,481,893 | June 21, 2024 | May 31, 2027 | GREENHOUSE, BRYAN R | reporter.nih.gov |
| Epigenetic drivers of quiescence in artemisinin-resistant Plasmodium falciparum malaria | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $1,480,500 | September 3, 2024 | August 31, 2027 | SMALL-SAUNDERS, JENNIFER L. | reporter.nih.gov |
| Characterization of Ionotropic Receptors in Mating and Blood Feeding in Anopheles mosquitoes | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,479,639 | June 2, 2023 | May 31, 2028 | ZWIEBEL, LAURENCE J | reporter.nih.gov |
| Spatial, temporal, and functional study of the basal complex in Plasmodium falciparum | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,475,886 | March 18, 2024 | January 31, 2029 | DVORIN, JEFFREY D | reporter.nih.gov |
| Nqo2 in Primaquine-Induced Hemolysis of G6PD-deficient RBCs | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,463,166 | May 15, 2024 | April 30, 2028 | GOLDFARB, ADAM N. | reporter.nih.gov |
| From bench to bednet: Developing novel mitochondrial inhibitors for killing Plasmodium in the malaria mosquito | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,461,927 | December 18, 2023 | October 31, 2028 | CATTERUCCIA, FLAMINIA | reporter.nih.gov |
| Multivalent mRNA-based malaria vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,456,890 | August 1, 2024 | July 31, 2029 | BURNS, JAMES MATTHEW | reporter.nih.gov |
| Environmental determinants of KSHV transmission in rural Uganda | NIH | National Cancer Institute | 2021 to 2023 | $1,454,511 | June 7, 2019 | July 31, 2024 | SABOURIN, KATHERINE R | reporter.nih.gov |
| Exploiting cross-reactive, conserved epitopes in Plasmodium vivax to develop a vaccine against falciparum placental malaria. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,453,074 | March 10, 2020 | February 28, 2027 | YANOW, STEPHANIE | reporter.nih.gov |
| Determinants of apicoplast maintenance in malaria parasites | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,435,500 | May 20, 2016 | April 30, 2028 | PRIGGE, SEAN TAYLOR | reporter.nih.gov |
| Structural Vaccinology and Design of Novel Imunogens for Malaria Vaccine Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,430,568 | February 1, 2018 | January 31, 2024 | GOLDBERG, DANIEL E. | reporter.nih.gov |
| Human-informed data-driven development of next-generation T cell vaccine against malaria | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,424,256 | September 2, 2022 | August 31, 2026 | DOOLAN, DENISE L. | reporter.nih.gov |
| Tracking the flow of malaria parasites and drug resistance within the DRC and across its borders | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,422,383 | June 21, 2018 | May 31, 2024 | BAILEY, JEFFREY A. | reporter.nih.gov |
| RDT-undetectable Malaria in the DR Congo: Epidemiology and Development of Alternatives | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,422,114 | February 22, 2018 | January 31, 2024 | JULIANO, JONATHAN J | reporter.nih.gov |
| Boron-containing antimalarial drug discovery | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $1,417,295 | July 8, 2020 | September 2, 2024 | BAKER, STEVE | reporter.nih.gov |
| Hit-to-Lead Development of the Kalihinol Scaffold for Malaria Treatment | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,406,400 | September 21, 2018 | August 31, 2024 | VANDERWAL, CHRISTOPHER D | reporter.nih.gov |
| Malaria diagnostic testing and conditional subsidies to target ACTs in the retail sector: the TESTsmART trial | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,404,675 | September 14, 2018 | August 31, 2024 | PRUDHOMMEOMEARA, WENDY | reporter.nih.gov |
| Plasmodium vivax Erythrocyte Invasion Mechanisms and Humoral Immune Response in Duffy Negative Africans | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,400,309 | February 9, 2022 | January 31, 2027 | LO, EUGENIA | reporter.nih.gov |
| Defining and Exploiting the Circadian Clocks in Malaria Parasites | NIH | National Institute of General Medical Sciences | 2023 | $1,399,125 | September 25, 2023 | August 31, 2026 | RIJO-FERREIRA, FILIPA | reporter.nih.gov |
| Regulation of the Immune Response to Plasmodium by IL-10 Producing Natural Killer Cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,392,951 | February 8, 2019 | January 31, 2025 | HAMILTON HART, SARA ELIZABETH | reporter.nih.gov |
| Training and Research on Severe Malarial Anemia | NIH | Fogarty International Center | 2021 to 2025 | $1,391,750 | April 22, 2002 | February 28, 2027 | PERKINS, DOUGLAS JAY | reporter.nih.gov |
| Noncoding DNA regulatory elements and Anopheles vector biology | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,390,052 | February 1, 2020 | January 31, 2026 | RIEHLE, MICHELLE M | reporter.nih.gov |
| Protein glycosylation and trafficking in Plasmodium falciparum | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,388,153 | June 6, 2024 | April 30, 2029 | MURALIDHARAN, VASANT | reporter.nih.gov |
| Development and function of CD4+ memory T cells during malaria | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,385,505 | June 15, 2016 | January 31, 2028 | BUTLER, NOAH SULLIVAN | reporter.nih.gov |
| Regulation of Plasmodium-specific CD4+ T cells | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,385,505 | September 26, 2016 | January 31, 2028 | BUTLER, NOAH SULLIVAN | reporter.nih.gov |
| Brain endothelial barrier disruption during cerebral malaria | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,381,992 | May 15, 2024 | March 31, 2029 | RODRIGUEZ, ANA | reporter.nih.gov |
| Molecular Mechanisms in Pediatric Cerebral Malaria Pathogenesis and Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,375,854 | August 1, 2019 | July 31, 2024 | SMITH, JOSEPH D | reporter.nih.gov |
| Functional assays of Plasmodium vivax DBP, EBP, and RBP2b in erythrocyte invasion in Duffy-Negative Africans | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $1,372,763 | February 9, 2022 | October 1, 2023 | LO, EUGENIA | reporter.nih.gov |
| Dissecting mRNA-ribosome interaction in AU-rich transcriptome of Plasmodium falciparum | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $1,371,447 | June 1, 2021 | March 31, 2025 | DJURANOVIC, SERGEJ | reporter.nih.gov |
| Impacts of Environment, Host Genetics and Antigen Diversity on Malaria Vaccine Efficacy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,363,169 | March 1, 2018 | February 28, 2025 | BAILEY, JEFFREY A. | reporter.nih.gov |
| Repeat Ivermectin Mass Drug Administrations for MALaria control II (RIMDAMAL II): a double-blind cluster randomized trial for integrated control of malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,352,862 | August 1, 2018 | July 31, 2024 | FOY, BRIAN DAVID | reporter.nih.gov |
| In vitro modeling of blood brain barrier dysfunction on a chip to elucidate the pathogenesis of cerebral malaria | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,352,800 | September 15, 2021 | August 31, 2026 | GOLIGHTLY, LINNIE | reporter.nih.gov |
| Chromatin structure and control of gene expression in the human malaria parasite | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,350,090 | May 2, 2018 | April 30, 2025 | LE ROCH, KARINE GAELLE | reporter.nih.gov |
| Deciphering mechanisms of CD4+ T cell-dependent clinical immunity to repeated Plasmodium infections | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,327,045 | March 15, 2024 | January 31, 2029 | JAGANNATHAN, PRASANNA | reporter.nih.gov |
| ER-shaping proteins of Plasmodium | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,319,152 | June 1, 2021 | May 31, 2023 | BHANOT, PURNIMA | reporter.nih.gov |
| The genetic basis of emerging multidrug resistance in Plasmodium falciparum African malaria | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,318,091 | March 11, 2024 | January 31, 2029 | MOK, SACHEL | reporter.nih.gov |
| Defining the complex genetic basis of Plasmodium falciparum resistance to artemisinin and quinine and identifying resistance-refractory therapeutics | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,297,430 | May 17, 2024 | March 31, 2029 | FIDOCK, DAVID A | reporter.nih.gov |
| The mutagenic chain reaction: a method for autocatalyic gene dissemination | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $1,295,344 | April 1, 2016 | March 31, 2025 | BIER, ETHAN | reporter.nih.gov |
| Impact of early childhood malaria prevention on malaria risk at school entry (ERASE) | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,276,157 | July 10, 2024 | May 31, 2029 | HARRISON, SHANNON TAKALA | reporter.nih.gov |
| Inflammatory Suppression of Adaptive Immunity by Plasmodium MIF | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,256,250 | April 1, 2014 | April 30, 2025 | BUCALA, RICHARD J | reporter.nih.gov |
| Regional Centre for Vector Borne Diseases in West Africa (RCVBD) | NIH | Fogarty International Center | 2021 to 2025 | $1,242,000 | March 16, 2021 | February 28, 2026 | AFRANE, YAW ASARE | reporter.nih.gov |
| Malaria and Mosquito/Tick-borne Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,232,416 | July 1, 2019 | July 31, 2030 | SULLIVAN, DAVID JOSEPH | reporter.nih.gov |
| Repurposing kinase inhibitor chemotypes as antimalarials | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,217,031 | April 3, 2020 | March 31, 2026 | CHIBALE, KELLY | reporter.nih.gov |
| Training in Malaria Epidemiology, Translational Research, and Implementation Science to Strengthen Malaria Policy and Control in Uganda | NIH | Fogarty International Center | 2021 to 2025 | $1,187,583 | June 1, 2017 | December 31, 2027 | KAMYA, MOSES ROBERT | reporter.nih.gov |
| Determinants of malaria transmission by submicroscopic gametocytemia | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,187,247 | June 22, 2018 | May 31, 2024 | LIN, JESSICA | reporter.nih.gov |
| Temporal strain structure and response to interventions in a high endemicity region of Plasmodium falciparum | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,178,028 | July 19, 2019 | September 1, 2023 | PASCUAL, MERCEDES | reporter.nih.gov |
| Proton pumping and energy metabolism of the ring stage malaria parasites | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,163,818 | June 17, 2024 | April 30, 2029 | KE, HANGJUN | reporter.nih.gov |
| Malaria variant surface antigen expression and vulnerability to disease in Malian children with Hemoglobin C trait | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $1,156,266 | July 15, 2019 | June 30, 2025 | TRAVASSOS, MARK A | reporter.nih.gov |
| Cluster randomized trial of intermittent preventive treatment of malaria in school-agechildren to improve the health of students and decrease community transmission(CRITICal) | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,126,029 | August 7, 2025 | June 30, 2030 | DORSEY, MATTHEW G | reporter.nih.gov |
| RAPs-mediated post-transcriptional control in Apicomplexan parasites | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,121,140 | September 19, 2018 | August 31, 2025 | LE ROCH, KARINE GAELLE | reporter.nih.gov |
| Multi-target blood stage vaccine against Plasmodium falciparum | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,107,549 | December 13, 2019 | November 30, 2026 | RAJ, DIPAK KUMAR | reporter.nih.gov |
| PTEX mechanism in malaria parasite effector protein export and host cell subversion | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,098,864 | July 1, 2023 | June 30, 2028 | BECK, JOSH RYAN | reporter.nih.gov |
| The protease network that regulates innate immunity in mosquitoes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,082,384 | September 13, 2018 | August 31, 2025 | MICHEL, KRISTIN | reporter.nih.gov |
| Mali-Guinea Research Leadership Training Program for Sustainable control and elimination of Malaria and Neglected tropical diseases | NIH | Fogarty International Center | 2021 to 2025 | $1,068,308 | June 1, 2010 | December 31, 2027 | DOUMBIA, SEYDOU | reporter.nih.gov |
| Optimizing Benefits While Reducing Risks of Iron in Malaria-Endemic Areas | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $1,062,973 | July 5, 2018 | May 31, 2024 | CUSICK, SARAH | reporter.nih.gov |
| Role of TAM receptors in modulating humoral immunity against parasitic infections | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,041,618 | September 5, 2024 | August 31, 2029 | VIJAY, RAHUL | reporter.nih.gov |
| PROTOZOAN PURINE PHOSPHORIBOSYLTRANSFERASES AS TARGETS TO TREAT MALARIA, AFRICAN TRYPANOSOMIASIS AND CHAGAS'S DISEASE | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,003,662 | September 25, 2017 | August 31, 2023 | MEEK, THOMAS | reporter.nih.gov |
| Malarial Retinopathy Screening System for Improved Diagnosis of Cerebral Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,000,000 | June 1, 2014 | November 30, 2023 | JOSHI, VINAYAK S | reporter.nih.gov |
| PfSPZ Vaccine for Prevention of Plasmodium falciparum malaria | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $988,772 | September 1, 2022 | June 30, 2024 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| Novel Plasmodial Surface Anion Channel Inhibitors as Antimalarial Drugs | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $982,478 | September 21, 2012 | May 31, 2023 | BUTLER, MICHELLE M. | reporter.nih.gov |
| Training in Malaria Research in Myanmar | NIH | Fogarty International Center | 2021 to 2025 | $978,258 | March 15, 2021 | February 28, 2027 | CUI, LIWANG | reporter.nih.gov |
| Mentoring translational scientists in international infectious disease research | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $969,511 | January 22, 2019 | December 31, 2028 | GREENHOUSE, BRYAN R | reporter.nih.gov |
| An MRI Ancillary Study of Malaria Fever Control RCT | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $969,288 | March 15, 2020 | April 30, 2025 | BIRBECK, GRETCHEN L. | reporter.nih.gov |
| Preparing for a world with artemisinin resistance: using individual-based epidemiological modeling to minimize the long-term detrimental effects of antimalarial drug resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $966,314 | August 10, 2020 | December 31, 2023 | BONI, MACIEJ F | reporter.nih.gov |
| Predicting Epilepsy in Cerebral Malaria: Working Toward Identifying Biomarkers of Epileptogenesis in Children | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $961,585 | September 1, 2021 | December 31, 2025 | PATEL, ARCHANA A. | reporter.nih.gov |
| Elucidating the trafficking mechanisms of effector proteins to the Plasmodium infected red blood cell | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $935,451 | January 11, 2022 | December 31, 2023 | MURALIDHARAN, VASANT | reporter.nih.gov |
| Mapping Drug Resistance Genes in Plasmodium falciparum | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $923,047 | September 1, 2000 | November 30, 2022 | ANDERSON, TIM J | reporter.nih.gov |
| Essential functions of the mitochondrion in malaria parasites | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $921,732 | August 20, 2024 | July 31, 2029 | RAJARAM, KRITHIKA | reporter.nih.gov |
| Elucidating the mechanism for malaria rhythmicity: an underlying circadian clock of the parasite | NIH | National Institute of General Medical Sciences | 2022 to 2024 | $894,503 | September 18, 2019 | April 30, 2026 | RIJO-FERREIRA, FILIPA | reporter.nih.gov |
| Mentoring in Translational Malaria Genomics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $868,031 | January 12, 2018 | December 31, 2027 | JULIANO, JONATHAN J | reporter.nih.gov |
| Serological markers of natural immunity to Plasmodium falciparum infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $858,047 | July 12, 2021 | January 23, 2026 | FRIEDMAN-KLABANOFF, DEANNA | reporter.nih.gov |
| Geo-enabled detect and respond system for antimalarial resistance in Ghana: GDRS - Ghana | NIH | Fogarty International Center | 2023 to 2025 | $853,846 | February 23, 2024 | May 31, 2027 | ABIMIKU, ALASH'LE G. | reporter.nih.gov |
| Species-transcending prevention of mosquito vector infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $832,071 | November 14, 2024 | October 31, 2029 | SATHER, D. NOAH | reporter.nih.gov |
| Rapid, Point of Care Diagnostic for Malaria, highly sensitive for P. vivax, with species differentiation | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $827,800 | August 6, 2020 | July 31, 2022 | GALEN, PETER | reporter.nih.gov |
| mRNA-LNP vaccines targeting multiple stages and multiple species of human malaria parasite | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $813,160 | December 26, 2024 | November 30, 2029 | KUMAR, NIRBHAY | reporter.nih.gov |
| The function of atypical B cells in the immune response against malaria | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $812,704 | January 3, 2025 | December 31, 2026 | BUNNIK, EVELIEN MARGARETHA | reporter.nih.gov |
| Potent Antibody Protection Against P. falciparum and P. vivax Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $807,330 | August 12, 2025 | July 31, 2030 | DEKOSKY, BRANDON JAMES | reporter.nih.gov |
| Targeting mosquito complement to alter the specificity of the innate immune response | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $805,000 | May 4, 2018 | April 30, 2024 | POVELONES, MICHAEL JOSEPH | reporter.nih.gov |
| Improving the accuracy of malaria surveillance with serology and parasite genetic data | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $799,646 | December 8, 2021 | November 30, 2026 | BRIGGS, JESSICA | reporter.nih.gov |
| Kinase Targeted Antimalarial Agents | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $798,586 | December 16, 2019 | November 30, 2022 | ZUTSHI, REENA | reporter.nih.gov |
| Functional analysis of epigenetic regulators of malaria blood-stage proliferation and transmission | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $797,500 | February 20, 2018 | April 30, 2023 | DURAISINGH, MANOJ T | reporter.nih.gov |
| Elucidating ligand-receptor interactions required for Plasmodium vivax blood-stage infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $797,500 | July 1, 2018 | December 31, 2023 | DURAISINGH, MANOJ T | reporter.nih.gov |
| Deciphering the Role of Non-Coding RNAs in Gene Regulation | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $791,864 | December 1, 2024 | November 30, 2029 | LE ROCH, KARINE GAELLE | reporter.nih.gov |
| Innate-adaptive immune bridging in gravidity-dependent immunity against placental malaria: a multi-omics approach | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $789,442 | July 17, 2025 | June 30, 2030 | JAGANNATHAN, PRASANNA | reporter.nih.gov |
| A systems analysis to understand the differential pharmacokinetics and protective efficacy of anti-malarial monoclonal antibodies in field trials. | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $781,241 | August 5, 2025 | July 31, 2030 | TRAN, TUAN MANH | reporter.nih.gov |
| Genomic surveillance for artemisinin resistance in Africa: moving beyond a candidate gene approach | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $776,905 | December 1, 2024 | November 30, 2029 | HARRISON, SHANNON TAKALA | reporter.nih.gov |
| tRNA modification reprogramming in artemisinin-resistant Plasmodium falciparum: An epigenetic driver of resistance? | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $768,864 | September 1, 2021 | August 31, 2025 | SMALL-SAUNDERS, JENNIFER L. | reporter.nih.gov |
| Optimization of antimalarials targeting multiple life stages of the parasite | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $768,193 | August 4, 2021 | July 31, 2026 | CARLIER, PAUL R | reporter.nih.gov |
| Plasmepsin X function in Plasmodium | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $762,500 | January 2, 2018 | December 31, 2023 | GOLDBERG, DANIEL E. | reporter.nih.gov |
| Mentoring in patient-oriented research in global health | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $759,276 | January 11, 2016 | July 31, 2027 | LAUFER, MIRIAM K. | reporter.nih.gov |
| Target-specific antimalarial compound identification using phenotypic assays | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $753,000 | June 3, 2019 | May 31, 2024 | NILES, JACQUIN C | reporter.nih.gov |
| Automated Mobile Microscopy for Malaria Diagnosis and surveillance in Uganda | NIH | National Institute of Biomedical Imaging and Bioengineering | 2023 to 2025 | $751,421 | September 18, 2023 | July 31, 2026 | NAKASI, ROSE | reporter.nih.gov |
| Examining the mechanisms and optimization of malaria chemoprevention strategies to improve birth outcomes in Africa | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2025 | $743,488 | July 1, 2025 | June 30, 2028 | ROH, MICHELLE | reporter.nih.gov |
| Discovery of Antimalarials with Novel Mechanism of Action | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $740,914 | January 1, 2018 | December 31, 2023 | CHAKRABARTI, DEBOPAM | reporter.nih.gov |
| Malaria Management through an On-demand Diagnostic Approach using Novel Ionic Probes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $735,349 | May 15, 2019 | April 30, 2025 | BADU-TAWIAH, ABRAHAM | reporter.nih.gov |
| Identifying the targets of protective immunity to severe falciparum malaria | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $708,202 | December 20, 2024 | November 30, 2029 | KURTIS, JONATHAN D. | reporter.nih.gov |
| Chemosensory Mechanisms Driving Malaria Transmission | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $707,696 | November 15, 2024 | October 31, 2029 | MCMENIMAN, CONOR JAMES | reporter.nih.gov |
| Malaria vaccine evaluation in a novel infant NHP challenge model | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $706,000 | November 4, 2022 | October 31, 2025 | SHEARS, MELANIE JANET | reporter.nih.gov |
| Understanding Emerging artemisinin partner drug resistance in eastern Africa | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $705,896 | August 12, 2025 | July 31, 2030 | FERDIG, MICHAEL T | reporter.nih.gov |
| The Malaria Transfusion Risk (MATRix) Study | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $705,384 | May 3, 2020 | April 30, 2026 | BLOCH, EVAN MARTIN | reporter.nih.gov |
| Predicting the spread of antimalarial drug resistance using deep learning surrogates | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $703,807 | September 25, 2025 | August 31, 2030 | JULIANO, JONATHAN J | reporter.nih.gov |
| Discovery and preclinical evaluation of Plasmodium falciparum and P. vivax coiled coil antigens for malaria vaccine development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $702,029 | January 3, 2020 | December 31, 2022 | HERRERA VALENCIA, SOCRATES | reporter.nih.gov |
| Phenotype-based Screens to Identify Genetic Factors Associated with Gametocyte Development in Plasmodium falciparum | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $700,288 | November 12, 2024 | October 31, 2029 | ADAMS, JOHN H | reporter.nih.gov |
| Plasmodium and Anopheles midgut interactive proteins influence malaria transmission | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $699,814 | November 20, 2024 | October 31, 2029 | LI, JUN | reporter.nih.gov |
| Evolution and coevolution of invasive Anopheles stephensi and sympatric Plasmodium populations in Africa: A genomic investigation | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $695,801 | September 17, 2025 | August 31, 2026 | CARTER, TAMAR | reporter.nih.gov |
| Novel Genetic Mechanism of Artemisinin Resistance for Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $694,949 | April 5, 2013 | June 30, 2023 | WIRTH, DYANN F | reporter.nih.gov |
| Exploring the roles of acquired immunity and functional constraint in sculpting malaria antigenic diversity in a longitudinal cohort | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $694,822 | September 25, 2018 | October 31, 2024 | NEAFSEY, DANIEL E | reporter.nih.gov |
| Determinants of poor responsiveness to the booster dose of the RTS,S malaria vaccine in African children | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $690,500 | December 6, 2024 | November 30, 2029 | VALIM, CLARISSA | reporter.nih.gov |
| Next Generation ELQs for Treatment and Once-Monthly Protection Against Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $686,895 | September 2, 2024 | April 30, 2025 | RISCOE, MICHAEL KEVIN | reporter.nih.gov |
| Impact of early-life pathogen exposures on pre-erythrocytic malaria vaccine effectiveness in Kenyan infants | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $682,200 | August 22, 2025 | July 31, 2030 | DOBBS, KATHERINE ROSE | reporter.nih.gov |
| Neutrophil-driven mucosal dysfunction in SIV/malaria co-infection | NIH | Office of the Director, National Institutes of Health | 2021 to 2022 | $680,000 | April 1, 2021 | January 31, 2023 | MANUZAK, JENNIFER | reporter.nih.gov |
| Sickle Cell Anemia, Splenic Pathology, and Hydroxyurea in Sub-Saharan Africa | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $678,240 | July 21, 2020 | June 30, 2025 | SMART, LUKE | reporter.nih.gov |
| Characterizing the interaction between human and vector behaviors to enhance the impact of malaria control interventions in Uganda | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $675,962 | August 11, 2025 | July 31, 2030 | KREZANOSKI, PAUL JOSEPH | reporter.nih.gov |
| Emerging zoonotic malaria in Malaysia: strengthening surveillance and evaluating population genetic structure to improve regional risk prediction tools | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $674,176 | September 1, 2021 | August 31, 2026 | RAJAHRAM, GIRI | reporter.nih.gov |
| The age-specific impact of seasonal malaria chemoprevention on malaria incidence, antibody responses, and parasite reservoirs in Malian children | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $672,338 | April 23, 2021 | March 31, 2027 | COULIBALY, DRISSA | reporter.nih.gov |
| Red blood cell modifiers for Plasmodium falciparum growth in sickle cell disease erythrocytes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $671,760 | August 1, 2020 | April 30, 2025 | ARCHER, NATASHA MARIE BERNADETTE | reporter.nih.gov |
| Tfh responses to novel vaccine candidates and protection from pediatric falciparum malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $668,302 | August 11, 2017 | July 31, 2023 | KURTIS, JONATHAN D. | reporter.nih.gov |
| Memory Regulatory T cells in Recurring Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $650,020 | August 1, 2025 | July 31, 2030 | KURUP, SAM | reporter.nih.gov |
| Mosquito extracellular vesicles in malaria parasite killing and immune priming | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $648,924 | February 24, 2025 | January 31, 2030 | SMITH, RYAN C. | reporter.nih.gov |
| Regulation of brain endothelial integrity by angiotensin receptors as treatment for cerebral malaria | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2022 | $646,503 | June 1, 2018 | February 29, 2024 | RODRIGUEZ, ANA | reporter.nih.gov |
| Discovering the essential genome of Plasmodium falciparum | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $643,737 | June 15, 2018 | May 31, 2024 | ADAMS, JOHN H | reporter.nih.gov |
| Integrative Multiomics to Probe Interactions of the Gut Microbiome with Malaria Pathogenesis and Antimalarial Pharmacokinetics in Humans | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $636,193 | August 25, 2025 | July 31, 2030 | IPPOLITO, MATTHEW MICHAEL | reporter.nih.gov |
| Function of PfNCR1 at the PPM/PVM Interface | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $633,218 | July 17, 2025 | June 30, 2030 | GOLDBERG, DANIEL E. | reporter.nih.gov |
| Toward field-ready paratransgenesis for malaria: bacterial strain optimization and microbiota interactions | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $606,815 | April 18, 2025 | March 31, 2030 | LAMPE, DAVID J | reporter.nih.gov |
| Enhancing T and B cell responses to Plasmodium infection and vaccination via IL-15 | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $606,767 | June 20, 2024 | April 30, 2025 | BURRACK, KRISTINA STOERMER | reporter.nih.gov |
| Aggressive Antipyretics in CNS Malaria: A Randomized-Controlled Trial Assessing Antipyretic Efficacy and Parasite Clearance | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $602,537 | September 15, 2017 | May 31, 2023 | BIRBECK, GRETCHEN L. | reporter.nih.gov |
| Attenuation of Liquid Formulation for PfSPZ Vaccine by X-Ray | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $600,000 | April 12, 2021 | March 31, 2024 | JAMES, ERIC ROBERT | reporter.nih.gov |
| In vitro bioreactor production of a genetically modified late liver stage-arresting replication competent Plasmodium falciparum sporozoite vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $600,000 | June 3, 2022 | May 31, 2025 | SIM, B. KIM LEE | reporter.nih.gov |
| Epitope-directed monoclonal antibody production for mosquito immune cells (for malaria) | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $599,993 | September 1, 2023 | August 31, 2025 | YU, YANG | reporter.nih.gov |
| Conditional male lethal Anopheles stephensi line for the efficient manufacture of malaria vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $599,951 | February 14, 2023 | January 31, 2025 | BILLINGSLEY, PETER F. | reporter.nih.gov |
| Delivery of a candidate AgTRIOVx malaria vaccine by thermostable microneedle patches | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $599,740 | June 1, 2024 | May 31, 2027 | ANTHONY, KAREN G. | reporter.nih.gov |
| Spatial repellents to reduce the outdoor transmission of malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $599,147 | January 1, 2021 | June 30, 2025 | CHEN, INGRID TING-TING | reporter.nih.gov |
| The Development and Function of Plasmodium-specific memory B cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $596,609 | December 16, 2016 | November 30, 2022 | PEPPER, MARION | reporter.nih.gov |
| Identifying gaps between LLIN use and vector exposure to improve malaria control | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $591,145 | July 1, 2019 | December 31, 2024 | KREZANOSKI, PAUL JOSEPH | reporter.nih.gov |
| An instrument-free malaria diagnostic | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $588,900 | June 1, 2024 | May 31, 2026 | TOBIN, GREGORY JOHN | reporter.nih.gov |
| Next Generation ELQs for Treatment and Once-Monthly Protection Against Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $587,318 | May 1, 2025 | April 30, 2029 | RISCOE, MICHAEL KEVIN | reporter.nih.gov |
| Memory T follicular helper cell kinetics and localization during recall immune responses to tetanus vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $586,904 | August 12, 2019 | July 31, 2024 | FROSCH, ANNE ELIZABETH PARKER | reporter.nih.gov |
| Impact of gestational SARS-CoV-2 and maternal inflammation on child growth and neurodevelopment in a malaria-endemic setting | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $579,960 | September 1, 2023 | August 31, 2028 | JACOBSON, KAREN BLAKE | reporter.nih.gov |
| Genetic and social network analysis to target interventions for malaria elimination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $579,756 | July 22, 2020 | June 30, 2025 | SMITH, JENNIFER LINNEA | reporter.nih.gov |
| Kruppel-Like Factor 2 Counters Vascular and Immunologic Dysfunction in Child Cerebral Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $576,496 | February 15, 2017 | January 31, 2023 | KAZURA, JAMES WALTER | reporter.nih.gov |
| Mentoring Translational Researchers for Careers in Pediatric Global Health | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $574,659 | June 3, 2014 | June 30, 2025 | FEENEY, MARGARET E | reporter.nih.gov |
| Clinical Pharmacology of Malaria Control and Elimination: Pharmacodynamics ofArtemisinin-based Combination Agents and their Barriers to Drug Resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $574,240 | February 13, 2020 | January 31, 2025 | IPPOLITO, MATTHEW MICHAEL | reporter.nih.gov |
| Placental malaria: The role of inflammation at the maternal-fetal interface | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $569,958 | December 4, 2018 | November 30, 2023 | GAW, STEPHANIE LINA | reporter.nih.gov |
| Serial Killers to Mosquitos: The Spatial Targeting of Larval habitats in rural Uganda using geographic Profiling | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $564,641 | December 1, 2018 | November 30, 2024 | BOYCE, ROSS MATHEW | reporter.nih.gov |
| The Germinal Center and T cell help in Three Phases of Clearance of Plasmodium | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $564,054 | November 1, 2017 | July 15, 2022 | STEPHENS, ROBIN | reporter.nih.gov |
| Modularizing manufacture of PfSPZ vaccines: ookinete production for PfSPZ manufacture in mosquitoes and in vitro | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $559,942 | September 6, 2023 | August 31, 2025 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| Directed in vivo assembly of a robust biopolymer particle-based multistage malaria vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $549,032 | September 10, 2025 | August 31, 2028 | REHM, BERND | reporter.nih.gov |
| Discovering the Essential Genome of Plasmodium Falciparum | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $543,940 | June 15, 2018 | June 30, 2026 | ADAMS, JOHN H | reporter.nih.gov |
| Unravelling disease tolerance and host resistance in afebrile P. falciparum infections: a prospective study in Mozambican adults | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $540,228 | June 1, 2020 | May 31, 2026 | AIDE, PEDRO | reporter.nih.gov |
| Exocytosis of Plasmodium egress and invasion organelles | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $540,193 | August 22, 2023 | July 31, 2025 | MURALIDHARAN, VASANT | reporter.nih.gov |
| Antigen discovery for transmission-blocking vaccines in Plasmodium vivax | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $540,000 | April 6, 2020 | February 28, 2025 | CAO, YAMING | reporter.nih.gov |
| Monitoring the development of resistance to the novel insecticide clothianidin in Anopheles gambiae | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $540,000 | May 1, 2020 | April 30, 2025 | KAMGANG, BASILE | reporter.nih.gov |
| The Skin Phase of Malaria Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $536,335 | July 6, 2017 | June 30, 2024 | SINNIS, PHOTINI | reporter.nih.gov |
| Impact of malaria vector diversity on intervention strategies | NIH | Fogarty International Center | 2021 to 2024 | $534,732 | September 18, 2020 | August 31, 2025 | MCCANN, ROBERT SEAN | reporter.nih.gov |
| "Investigating the rebound effects of seasonal malaria chemoprevention (SMC) in Mali" | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $525,914 | September 5, 2022 | August 31, 2027 | TOURE, MAHAMOUDOU | reporter.nih.gov |
| Preparing for a world with artemisinin resistance: using individual-based epidemiological modeling to minimize the long-term detrimental effects of antimalarial drug resistance | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $523,000 | August 10, 2020 | July 31, 2025 | BONI, MACIEJ F | reporter.nih.gov |
| Evaluating the impact of pre-existing humoral immunity on hepatocyte death | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $516,175 | June 23, 2025 | May 31, 2027 | KAUSHANSKY, ALEXIS | reporter.nih.gov |
| Risk stratification of malaria among school-age children with mHealth spectroscopy of blood analysis | NIH | Fogarty International Center | 2024 to 2025 | $513,058 | September 1, 2022 | May 31, 2027 | KIM, YOUNG L | reporter.nih.gov |
| Novel artemisinin derivatives for chemogenomic profiling of Plasmodium falciparum | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $512,118 | June 1, 2020 | May 31, 2024 | CARVALHO, PAULO BATISTA DE | reporter.nih.gov |
| Role of the gut microbiota in shaping severity of malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $511,182 | January 11, 2017 | December 31, 2022 | SCHMIDT, NATHAN | reporter.nih.gov |
| Epidemiology of Malaria Invasion in Mutare City and Targets for Elimination, Zimbabwe | NIH | Fogarty International Center | 2021 to 2025 | $506,128 | September 17, 2021 | May 31, 2026 | MHARAKURWA, SUNGANO | reporter.nih.gov |
| Development of phenolic small molecule inhibitors of PfATP6, a Plasmodium calcium ATPase | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $502,201 | May 1, 2023 | April 30, 2027 | PAULA, STEFAN FRANZ | reporter.nih.gov |
| Cryo-ET structure of the Plasmodium basal complex | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $501,800 | August 4, 2025 | July 31, 2027 | DVORIN, JEFFREY D | reporter.nih.gov |
| Identifying the targets of protective immunity to severe falciparum malaria | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $500,144 | September 4, 2023 | August 31, 2024 | KURTIS, JONATHAN D. | reporter.nih.gov |
| Human-informed data-driven development of next-generation T cell vaccine against malaria | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $495,904 | September 2, 2022 | January 1, 2023 | DOOLAN, DENISE L. | reporter.nih.gov |
| Determining Mechanisms of Cerebral Blood Flow and Metabolism Derangements in Pediatric Cerebral Malaria (FLOW) | NIH | National Institute of Neurological Disorders and Stroke | 2024 | $490,977 | May 15, 2024 | April 30, 2026 | OBRIEN, NICOLE | reporter.nih.gov |
| Empowering functional genomics of An. gambiae through inversion genotyping | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $490,582 | February 14, 2017 | January 31, 2024 | BESANSKY, NORA JESSIE | reporter.nih.gov |
| Functional characterization of striated fiber assemblins in malaria parasites | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $486,750 | August 21, 2023 | July 31, 2025 | DVORIN, JEFFREY D | reporter.nih.gov |
| Generating a novel dual stage malaria vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $485,375 | September 24, 2021 | August 31, 2023 | PEPPER, MARION | reporter.nih.gov |
| Multiplex analysis of IgA and IgG antibody responses to early childhood malaria infections to inform vaccine development | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $482,617 | May 2, 2023 | April 30, 2026 | BERRY, ANDREA | reporter.nih.gov |
| Collaborative Research: Impacts of the African Origin of Plasmodium vivax on Contemporary Parasite Populations | NIH | Fogarty International Center | 2021 | $479,595 | July 20, 2017 | March 31, 2023 | JULIANO, JONATHAN J | reporter.nih.gov |
| Mechanisms Governing Translational Regulation During Plasmodium Transmission | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $477,453 | November 1, 2016 | August 31, 2024 | LINDNER, SCOTT E | reporter.nih.gov |
| Mechanisms of acute kidney injury in malaria - Resubmission - 1 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $476,248 | December 15, 2020 | November 30, 2023 | RODRIGUEZ, ANA | reporter.nih.gov |
| A Chemical Vaccine for Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $473,670 | September 19, 2019 | August 31, 2023 | SHAPIRO, THERESA A | reporter.nih.gov |
| Investigating the Mechanisms Underlying Mosquito Infectiousness in Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $472,836 | June 6, 2024 | April 30, 2027 | SINNIS, PHOTINI | reporter.nih.gov |
| Molecular Determinants of Sporozoite / Host Cell Interactions | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $470,750 | July 9, 2018 | June 30, 2022 | KAPPE, STEFAN HI | reporter.nih.gov |
| Novel nanoparticles function as chemo- and adjunctive-therapy against experimental cerebral malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $468,500 | December 1, 2020 | November 30, 2023 | VAN DER HEYDE, HENRI C | reporter.nih.gov |
| New strategies to study malaria-induced acute kidney injury | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $467,755 | September 15, 2021 | August 31, 2024 | GALLEGO-DELGADO, JULIO | reporter.nih.gov |
| Mechanisms of anemia in malaria | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $466,125 | June 13, 2024 | April 30, 2026 | RODRIGUEZ, ANA | reporter.nih.gov |
| Measuring the transmissibility of recurrent parasitemias that arise following artemisinin-based combination therapy | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $465,093 | January 17, 2024 | November 30, 2026 | LIN, JESSICA | reporter.nih.gov |
| Molecular Genetics of Avian Malaria Viruses | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $465,000 | May 1, 2022 | March 31, 2027 | SEHGAL, RAVINDER NATH MARIUS | reporter.nih.gov |
| Development and Composition of the Basal Complex During Plasmodium Sporogony | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $463,973 | May 23, 2024 | September 30, 2026 | LINDNER, SCOTT E | reporter.nih.gov |
| Identifying adjunctive therapy in the experimental model of malaria to improve cerebral malaria outcomes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $462,000 | June 11, 2021 | May 31, 2024 | DAILY, JOHANNA PATRICIA | reporter.nih.gov |
| Malaria and allergic inflammatory changes to the gut barrier | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $460,341 | June 1, 2018 | May 31, 2024 | LUCKHART, SHIRLEY | reporter.nih.gov |
| Designing a diversity-covering multiantigen multi-strain malaria vaccine | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $457,659 | August 2, 2019 | July 31, 2025 | OUATTARA, AMED | reporter.nih.gov |
| Parasite-specific proteasome inhibitors to combat multi-drug resistant malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $454,467 | December 9, 2016 | February 28, 2023 | BOGYO, MATTHEW | reporter.nih.gov |
| Mitigation of erythrocyte adhesion in human malaria | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $453,750 | July 9, 2024 | November 30, 2026 | CHISHTI, ATHAR H. | reporter.nih.gov |
| Precise field-friendly methods for quantification of antimalarial drugs in dried blood spots | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $451,000 | July 17, 2024 | May 31, 2027 | HUANG, LIUSHENG | reporter.nih.gov |
| Comprehensive, high-resolution arrays to trace the development of antibody responses to variant Plasmodium falciparum antigens in naturally exposed cohorts | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $451,000 | August 15, 2025 | July 31, 2027 | GREENHOUSE, BRYAN R | reporter.nih.gov |
| Complete Plasmodium falciparum infection cycle model | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $450,313 | November 7, 2022 | October 31, 2025 | DIMOPOULOS, GEORGE | reporter.nih.gov |
| Effect of gut microbiota composition on malaria vaccine-induced immune responses | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $449,728 | June 24, 2024 | April 30, 2026 | SCHMIDT, NATHAN | reporter.nih.gov |
| Parasite variant surface antigen expression and immune gaps in severe malaria | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $448,550 | July 9, 2024 | May 31, 2027 | TRAVASSOS, MARK A | reporter.nih.gov |
| Deciphering the role of Plasmodium falciparum plasmepsin 2/3 amplifications in mutant pfcrt-driven piperaquine resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $445,500 | March 18, 2021 | February 29, 2024 | FIDOCK, DAVID A | reporter.nih.gov |
| Characterization of Plasmodium falciparum long non-coding RNAs and their roles in gene regulation | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $445,488 | July 1, 2025 | June 30, 2027 | SERRE, DAVID | reporter.nih.gov |
| Longitudinal cohort study of SARS-CoV2 sero-conversion in a malaria-endemic community in Western Kenya | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $445,240 | December 10, 2021 | November 30, 2024 | TAYLOR, STEVE MYER | reporter.nih.gov |
| Assessing the role of liver stage antigens-specific antibodies against Plasmodium falciparum liver stage infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $445,142 | April 15, 2021 | October 31, 2024 | KRZYCH, URSZULA | reporter.nih.gov |
| Unbound piperaquine pharmacokinetic exposure in Ugandan pregnant women and children receiving malaria chemoprevention | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $444,125 | June 28, 2021 | May 31, 2024 | HUANG, LIUSHENG | reporter.nih.gov |
| Delineating host, parasite and pharmacologic factors impacting the treatment of malaria in children with and without HIV | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2023 | $441,844 | September 7, 2022 | August 31, 2025 | PARIKH, SUNIL | reporter.nih.gov |
| Novel Dual-Stage Antimalarials: Machine learning prediction, validation and evolution | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $441,319 | July 3, 2023 | December 31, 2025 | FREUNDLICH, JOEL STEPHEN | reporter.nih.gov |
| Discovering resistance-resistant antimalarial drug target | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $441,100 | June 23, 2023 | May 31, 2026 | LLINAS, MANUEL | reporter.nih.gov |
| Non-invasive detection of malaria parasites in vitro and in Cameroonian adults | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $439,420 | April 25, 2022 | March 31, 2025 | PARIKH, SUNIL | reporter.nih.gov |
| Developing a barcoded malaria parasite panel to assess broadly neutralizing antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $438,625 | June 29, 2022 | November 30, 2024 | DURAISINGH, MANOJ T | reporter.nih.gov |
| Evaluating host-directed therapeutics against blood-stage malaria parasites | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $438,625 | July 14, 2022 | June 30, 2024 | DURAISINGH, MANOJ T | reporter.nih.gov |
| Linking metabolite sensing and gene expression in malaria parasites | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $438,625 | November 9, 2022 | October 31, 2025 | DURAISINGH, MANOJ T | reporter.nih.gov |
| Understanding Plasmodium vivax transmission networks through a novel microhaplotype and kinship analysis approach | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $437,625 | August 1, 2025 | July 31, 2027 | HEMMING-SCHROEDER, ELIZABETH ANNE | reporter.nih.gov |
| A chromosome-level genome assembly for the major African malaria vector Anopheles gambiae | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $435,912 | February 5, 2021 | January 31, 2025 | SHARAKHOV, IGOR V | reporter.nih.gov |
| Fungal metabolites block malaria transmission | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $435,341 | July 15, 2017 | June 30, 2024 | LI, JUN | reporter.nih.gov |
| Structure of Malaria Parasite RNA polymerase | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $435,023 | January 21, 2022 | December 31, 2024 | MURAKAMI, KATSUHIKO | reporter.nih.gov |
| Understanding immune regulation in blood-stage malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $433,809 | May 1, 2012 | June 30, 2022 | HARTY, JOHN T | reporter.nih.gov |
| Buy the world a coke and keep it mosquito free | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $433,303 | June 18, 2025 | May 31, 2027 | SCHEEL, MOLLY DUMAN | reporter.nih.gov |
| Investigating gene regulatory networks in immune cells of children who differ in susceptibility to malaria infection using single-cell approaches | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $432,218 | January 1, 2021 | June 30, 2024 | TRAN, TUAN MANH | reporter.nih.gov |
| Development of Novel Natural Product Inspired Antileishmanial Drugs | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $431,186 | April 2, 2021 | March 31, 2024 | LANDFEAR, SCOTT M | reporter.nih.gov |
| Specificity of Plasmodium falciparum protein export | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $430,834 | June 1, 2022 | May 31, 2024 | GOLDBERG, DANIEL E. | reporter.nih.gov |
| The Impact of Novel Vector Control Tools on Asymptomatic Plasmodium falciparum Infection Prevalence and Transmission Potential | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $430,375 | June 10, 2024 | April 30, 2027 | KOEPFLI, CRISTIAN | reporter.nih.gov |
| Deciphering P. falciparum artemisinin resistance in Bangladesh: a genotypic-phenotypic evaluation of Kelch13 dependent and independent determinants | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $430,375 | May 31, 2024 | March 31, 2027 | MUKHERJEE, ANGANA | reporter.nih.gov |
| Silencing Anopheles stephensi | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $429,931 | November 16, 2023 | October 31, 2025 | SCHEEL, MOLLY DUMAN | reporter.nih.gov |
| High throughput chemoenzymatic synthesis of antimalarial compounds | NIH | National Center for Complementary & Integrative Health | 2022 to 2023 | $429,000 | September 1, 2022 | August 31, 2025 | NARAYAN, ALISON | reporter.nih.gov |
| A chromatin structure informed exploration of gene regulation in Anopheles coluzzii | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $429,000 | June 25, 2025 | May 31, 2027 | RIEHLE, MICHELLE M | reporter.nih.gov |
| Computer Vision for Malaria Microscopy: Automated Detection and Classification of Plasmodium for Basic Science and Pre-Clinical Applications | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $428,284 | September 1, 2023 | August 31, 2025 | IPPOLITO, MATTHEW MICHAEL | reporter.nih.gov |
| Defining the effect of Plasmodium infection on Ebola virus vaccine efficacy | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $427,625 | August 11, 2023 | July 31, 2025 | MAURY, WENDY JEAN | reporter.nih.gov |
| Mechanism of neutrophil dysfunction by Plasmodium falciparum secreted histidine-rich protein II | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $427,625 | July 22, 2024 | May 31, 2027 | GOLDBERG, DANIEL E. | reporter.nih.gov |
| Paired inhibition of falciparum merozoite invasion | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $426,938 | August 1, 2025 | July 31, 2027 | SHAPIRO, THERESA A | reporter.nih.gov |
| Serological Biomarkers for Monitoring Human-Vector Contact by Invasive Anopheles stephensi in Africa | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $425,863 | February 2, 2024 | December 31, 2026 | YAN, GUIYUN | reporter.nih.gov |
| Developing resistance-breaking insecticides at mosquito muscarinic acetylcholine receptors to reduce malaria transmission | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $424,925 | August 20, 2021 | July 31, 2025 | GROSS, AARON DONALD | reporter.nih.gov |
| Design and Evaluation of a Plasmodium vivax ultra-dense peptide array | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $424,875 | March 15, 2021 | February 28, 2023 | SERRE, DAVID | reporter.nih.gov |
| Impact of infection complexity on P. falciparum sexual commitment and gametocytemia | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $424,875 | April 1, 2023 | March 31, 2026 | HARRISON, SHANNON TAKALA | reporter.nih.gov |
| Intracellular-acting antibodies for the prevention of malaria liver stage infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $423,500 | November 4, 2022 | October 31, 2024 | WILDER, BRANDON KEITH | reporter.nih.gov |
| Function of a putative iron transporter in the Plasmodium apicoplast | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $423,500 | May 16, 2024 | March 31, 2026 | SIGALA, PAUL A | reporter.nih.gov |
| Innate iNKT Cells Shape Organ-Specific Pathogenesis in Plasmodium Infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $423,500 | July 17, 2025 | June 30, 2027 | LAMB, TRACEY JANE | reporter.nih.gov |
| New tools for antimalarial target identification | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $422,977 | March 22, 2019 | February 28, 2025 | WICHT, KATHRYN JEAN | reporter.nih.gov |
| Development of genetic tools for the study of mosquito hemocytes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $420,750 | September 24, 2021 | August 31, 2024 | SMITH, RYAN C. | reporter.nih.gov |
| Molecular mechanism of gamete fusion in malaria parasite | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $420,750 | August 6, 2025 | July 31, 2027 | KUMAR, SUDHIR | reporter.nih.gov |
| Quantifying Redox Potentials for Artemisinin Resistant (ARTR) Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $419,760 | April 8, 2022 | March 31, 2025 | ROEPE, PAUL D. | reporter.nih.gov |
| Genetic and Immunological Control for Development of Asymptomatic Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $419,375 | June 1, 2021 | May 31, 2024 | LAMB, TRACEY JANE | reporter.nih.gov |
| Plasmodium ovale hypnozoite development and relapse: a coordinated in vivo in vitro study | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $417,602 | November 17, 2020 | October 31, 2024 | LIN, JESSICA | reporter.nih.gov |
| A Novel Hydrology-based Malaria Transmission Model and Field Applications | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $417,500 | November 7, 2022 | October 31, 2025 | YAN, GUIYUN | reporter.nih.gov |
| Training of machine learning algorithms for the classification of accelerometer-measured bednet use and related behaviors associated with malaria risk | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $416,901 | August 4, 2023 | July 31, 2025 | KREZANOSKI, PAUL JOSEPH | reporter.nih.gov |
| Integrating a pre-erythrocytic component into a multistage malaria vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $416,125 | November 12, 2020 | October 31, 2023 | BURNS, JAMES MATTHEW | reporter.nih.gov |
| Longitudinal Antibody Profiles Correlated with Protection from Malaria in Malawi | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $415,919 | January 8, 2021 | December 31, 2023 | VALIM, CLARISSA | reporter.nih.gov |
| Essential function of a putative glycosyltransferase in P. falciparum | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $415,250 | April 5, 2021 | March 31, 2024 | MURALIDHARAN, VASANT | reporter.nih.gov |
| Elucidating mechanisms for artemisinin-induced dormancy in Plasmodium falciparum | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $415,250 | August 16, 2023 | July 31, 2025 | KYLE, DENNIS E | reporter.nih.gov |
| Comparative transcriptomics of Plasmodium vivax strains to understand hypnozoite formation | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $415,250 | June 7, 2024 | April 30, 2027 | JOYNER, CHESTER J. | reporter.nih.gov |
| Sensitive and quantitative malaria diagnostic using nanoscale porous silicon. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $414,988 | November 24, 2020 | October 31, 2023 | WEISS, SHARON M | reporter.nih.gov |
| Investigating the role of oxygen on Plasmodium multiplication rate | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $414,537 | November 10, 2022 | October 31, 2025 | CORDY, REGINA J | reporter.nih.gov |
| PfVP1, a battery of the malaria parasite, is critical for ring stage development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $413,790 | November 10, 2020 | October 31, 2023 | KE, HANGJUN | reporter.nih.gov |
| Larval Ecology of Invasive Anopheles stephensi in Ethiopia | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $413,617 | February 7, 2024 | December 31, 2026 | ZHOU, GUOFA | reporter.nih.gov |
| Acute brain injury and blood-brain barrier dysfunction in cerebral malaria (ABC) | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $413,606 | February 15, 2022 | January 31, 2024 | DATTA, DIBYADYUTI | reporter.nih.gov |
| High Throughput Screening of Medicines for Malaria Ventures Chemical Libraries to Identify Novel Inhibitors of Candida auris | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $412,500 | April 6, 2021 | March 31, 2025 | LOPEZ-RIBOT, JOSE L. | reporter.nih.gov |
| Evaluation of Immunodominant fragments of PfGARP for malaria vaccine development | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $412,500 | July 3, 2025 | June 30, 2027 | RAJ, DIPAK KUMAR | reporter.nih.gov |
| Malaria parasite harbors a unique protein lysine methyltransferase targeting both chromatin and motility machinery | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $412,375 | May 24, 2023 | April 30, 2026 | MIAO, JUN | reporter.nih.gov |
| UIS2 function in establishing transport mechanisms at the malaria parasite-host cell interface | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $411,719 | November 10, 2022 | October 31, 2025 | BECK, JOSH RYAN | reporter.nih.gov |
| Perturbations of host cell signaling by a complex hepatotropic pathogen | NIH | National Institute of General Medical Sciences | 2021 | $411,599 | April 1, 2013 | February 19, 2023 | KAUSHANSKY, ALEXIS | reporter.nih.gov |
| Assessing the Impact of Treatment of Asymptomatic Malaria Infections on Inflammation and Cognition in Schoolchildren | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $410,699 | January 25, 2024 | November 30, 2025 | TRAN, TUAN MANH | reporter.nih.gov |
| Evolutionary Dynamics of Zoonotic Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $409,943 | January 25, 2023 | December 31, 2027 | GOLDBERG, AMY | reporter.nih.gov |
| Molecular mechanisms of Plasmodium fertilization | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $409,375 | December 7, 2016 | November 30, 2022 | JACOBS-LORENA, MARCELO | reporter.nih.gov |
| Regulation of macrophage function during acute infection with Plasmodium | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $409,172 | June 1, 2024 | April 30, 2026 | STUMHOFER, JASON S | reporter.nih.gov |
| Ecology and genetics of insecticide resistance in African malaria vectors | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $407,000 | March 1, 2016 | February 29, 2028 | AFRANE, YAW ASARE | reporter.nih.gov |
| Continuous in vitro culture and genetics of Plasmodium vivax in a bespoke blood cell bioreactor | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $406,450 | April 7, 2025 | March 31, 2028 | DURAISINGH, MANOJ T | reporter.nih.gov |
| Multi-target blood stage vaccine against Plasmodium falciparum | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $406,250 | December 13, 2019 | November 30, 2021 | RAJ, DIPAK KUMAR | reporter.nih.gov |
| Quantifying the dual threat of Plasmodium vivax and Anopheles stephensi in a P. falciparum endemic pre-elimination setting in sub-Saharan Africa | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $406,015 | August 1, 2023 | July 31, 2025 | PRUDHOMMEOMEARA, WENDY | reporter.nih.gov |
| Genomics and sero-epidemiology of Plasmodium falciparum malaria in a pre-elimination setting | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $401,331 | April 1, 2023 | March 31, 2028 | SAENZ, FABIAN ERNESTO | reporter.nih.gov |
| Profiling malarial lipid biosynthesis and key acyl-coenzyme A synthetase activities with fatty acid alkynes | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $400,625 | July 2, 2024 | May 31, 2027 | KLEMBA, MICHAEL | reporter.nih.gov |
| Anti-Malarial Drug Leads from Fungi | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $398,769 | May 21, 2021 | April 30, 2024 | OBERLIES, NICHOLAS H. | reporter.nih.gov |
| New approaches to measuring and containing the spatial spread of human pathogens | NIH | National Institute of General Medical Sciences | 2021 | $398,323 | August 15, 2017 | July 31, 2022 | BUCKEE, CAROLINE O'FLAHERTY | reporter.nih.gov |
| Transcranial Doppler Ultrasonography Clinical and Research Centers of Excellence in Sub-Saharan Africa | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $393,121 | August 1, 2021 | July 31, 2024 | OBRIEN, NICOLE | reporter.nih.gov |
| Characterizing malaria vector competence among natural populations of Anopheles | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $392,833 | December 15, 2020 | November 30, 2023 | LAUFER, MIRIAM K. | reporter.nih.gov |
| Establishing strains and conditions for long-term P. vivax cultures | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $392,710 | December 6, 2024 | November 30, 2027 | JOYNER, CHESTER J. | reporter.nih.gov |
| Disrupting Apicoplast DNA Replication in Plasmodium: Identifying Key Proteases for Antimalarial Therapy | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $385,816 | July 24, 2025 | June 30, 2027 | NELSON, SCOTT W. | reporter.nih.gov |
| Mechanisms Governing Translational Regulation During Plasmodium Transmission | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $385,703 | November 1, 2016 | October 31, 2021 | LINDNER, SCOTT E | reporter.nih.gov |
| Anopheles FBG: a novel malaria transmission-blocking vaccine target | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $384,730 | November 8, 2022 | October 31, 2025 | LI, JUN | reporter.nih.gov |
| Suppression of anti-malarial humoral immune responses by gamaherpesviruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $383,290 | March 1, 2017 | November 30, 2021 | LAMB, TRACEY JANE | reporter.nih.gov |
| Impact of P. falciparum diversity on transmission reducing immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $382,428 | July 1, 2018 | June 30, 2024 | COHEE, LAUREN M | reporter.nih.gov |
| Gene delivery for Anopheles mosquitoes | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $380,762 | May 10, 2017 | April 30, 2024 | RASGON, JASON L | reporter.nih.gov |
| Epigenetic Reprogramming of Monocyte Functions during Acute Uncomplicated Malaria in Kenyan Children | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $379,150 | January 24, 2018 | December 31, 2023 | DOBBS, KATHERINE ROSE | reporter.nih.gov |
| Analysis of active genetic elements in germline and somatic cell lineages | NIH | National Institute of General Medical Sciences | 2025 | $376,498 | August 1, 2025 | July 31, 2030 | BIER, ETHAN | reporter.nih.gov |
| Functions of mRNPs in RNA metabolism in Plasmodium falciparum | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $375,000 | June 10, 2025 | May 31, 2030 | CUI, LIWANG | reporter.nih.gov |
| Mechanisms of Neuroinflammation in Experimental Cerebal Malaria | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $373,913 | September 1, 2018 | August 31, 2022 | STEPHENS, ROBIN | reporter.nih.gov |
| Characterizing the spatial epidemiology of urban malaria infection in Accra, Ghana (MUSE) | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $371,618 | February 28, 2023 | January 31, 2026 | STRESMAN, GILLIAN | reporter.nih.gov |
| Modulation of the B cell response to dengue virus infection by Plasmodium falciparum co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $370,546 | July 1, 2018 | June 30, 2024 | VU, DAVID MANH-TUNG | reporter.nih.gov |
| Synthesizing immunoinformatics and genetic epidemiology to identify signatures of natural functional immunity to malaria parasites | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $369,354 | March 1, 2023 | February 29, 2028 | MARKWALTER, CHRISTINE | reporter.nih.gov |
| Development of novel malaria pre-erythrocytic vaccine antigens targeting Plasmodium sporozoite liver infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $368,224 | January 4, 2023 | December 31, 2025 | CHA, SUNG-JAE | reporter.nih.gov |
| The development and evaluation of portable experimental huts for global malaria vector control decision-making | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $366,845 | August 18, 2025 | July 31, 2027 | MESSENGER, LOUISA ALEXANDRA | reporter.nih.gov |
| High-throughput mapping of human antibody sequences to PfEMP1 malaria antigen specificity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $360,399 | July 7, 2021 | June 30, 2024 | HVIID, LARS | reporter.nih.gov |
| EphA2 mediates opening of the blood brain barrier in cerebral malaria | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $356,155 | March 1, 2017 | February 28, 2023 | LAMB, TRACEY JANE | reporter.nih.gov |
| Blood-Biomarkers and Risk Factors of Acute Brain Injury associated with Neurodisability in Ugandan Children [BRAIN-Child] | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $351,649 | August 15, 2022 | July 31, 2025 | DATTA, DIBYADYUTI | reporter.nih.gov |
| The Effect of Maternal Cells on Infant Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $341,450 | December 12, 2017 | July 31, 2023 | HARRINGTON, WHITNEY ELIZABETH | reporter.nih.gov |
| Reducing malaria in pregnancy through focal drug administration in household members: A pilot feasibility trial | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $341,293 | June 1, 2025 | May 31, 2027 | BOYCE, ROSS MATHEW | reporter.nih.gov |
| Noguchi Institute Initiative for NTDs Elimination (NIINE) | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $339,541 | April 14, 2017 | March 31, 2023 | WILSON, MICHAEL D | reporter.nih.gov |
| Risk stratification of malaria among school-age children with mHealth spectroscopy of blood analysis | NIH | Fogarty International Center | 2022 to 2023 | $339,338 | September 1, 2022 | July 31, 2024 | KIM, YOUNG L | reporter.nih.gov |
| Large Scale systematic priorization of Plasmodium vivax blood stage vaccine antigens | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $318,040 | February 14, 2018 | January 31, 2023 | RAYNER, JULIAN CHARLES | reporter.nih.gov |
| Mechanisms of Neuroinflammation in Experimental Cerebal Malaria | NIH | National Institute of Neurological Disorders and Stroke | 2023 | $308,938 | September 1, 2022 | August 31, 2024 | STEPHENS, ROBIN | reporter.nih.gov |
| A systems biology investigation of the interplay between gut microbes and blood metabolites in the development of malarial anemia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $305,027 | August 20, 2018 | July 31, 2024 | CORDY, REGINA J | reporter.nih.gov |
| Mathematical modeling of immune response to malaria | NIH | National Institute of General Medical Sciences | 2021 | $303,690 | March 1, 2017 | February 28, 2023 | GANUSOV, VITALY V. | reporter.nih.gov |
| A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stage. | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $300,000 | April 21, 2020 | March 31, 2023 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| Development of Monoclonal Antibody-mediated Interventions to Combat Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $300,000 | July 5, 2022 | GAO, WENDA | reporter.nih.gov | |
| NOVEL DIAGNOSTIC BIOMARKERS DISCOVERY AND VALIDATION FOR MALARIA | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $300,000 | December 1, 2024 | November 30, 2025 | LEDIZET, MICHEL | reporter.nih.gov |
| Enhancement of gametocytogenesis in Plasmodium falciparum by genetic engineering for improved PfSPZ Vaccine Manufacture | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $299,994 | August 17, 2020 | July 31, 2023 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| PfAg, a multivalent peptide vaccine against malaria | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $299,954 | September 15, 2025 | August 31, 2027 | CHUANG, YU-MIN | reporter.nih.gov |
| CRISPR-based Tropical Infection Diagnostics | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $299,937 | September 15, 2023 | September 14, 2024 | ZHUKOV, DMITRY | reporter.nih.gov |
| Development of monoclonal antibody-mediated interventions to combat malaria | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $299,777 | August 26, 2022 | MILLER, JACQUELINE | reporter.nih.gov | |
| A vaccine targeting mosquito metabolic pathways to eradicate malaria | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $299,644 | September 23, 2025 | August 31, 2027 | CHUANG, YU-MIN | reporter.nih.gov |
| Benzoxaborole-based antimalarial drug discovery | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $299,639 | July 8, 2020 | June 30, 2023 | AUBREY, MARISSA | reporter.nih.gov |
| CRISPR-Based in Vitro Diagnostic Device for Rapid Detection of Eukaryotic Pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $299,610 | September 15, 2023 | September 14, 2024 | SILVERMAN, ANDREW | reporter.nih.gov |
| Development of monoclonal antibody-mediated interventions to combat malaria | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $298,596 | August 30, 2022 | August 31, 2023 | RUPPRECHT, SUSAN | reporter.nih.gov |
| E. coli platform for expression of low-cost malaria fusion proteins | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $297,809 | January 1, 2024 | June 30, 2025 | LEES, ANDREW | reporter.nih.gov |
| Identification and validation of molecular markers of piperaquine resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $289,910 | February 3, 2017 | January 31, 2024 | HARRISON, SHANNON TAKALA | reporter.nih.gov |
| Delineating the kidney brain axis in children with severe malaria (KID-BRAIN) | NIH | Fogarty International Center | 2023 to 2025 | $289,502 | August 20, 2023 | April 30, 2028 | BATTE, ANTHONY | reporter.nih.gov |
| Role of primaquine pharmacokinetics in treatment efficacy for vivax malaria | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $284,968 | June 10, 2022 | May 31, 2023 | SPRING, MICHELE | reporter.nih.gov |
| The impact of antimalarials and insecticide resistance on malaria transmission in Uganda | NIH | Fogarty International Center | 2021 to 2022 | $282,448 | September 21, 2018 | January 31, 2023 | CONRAD, MELISSA D | reporter.nih.gov |
| Real-World Impact of Next Generation Insecticidal Nets for Malaria Control in Rural Western Kenya | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $280,939 | April 1, 2024 | March 31, 2029 | MANGENI, JUDITH | reporter.nih.gov |
| Functional characterization of the Plasmodium falciparum invasion ligand bindome | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $277,318 | May 16, 2024 | May 14, 2025 | KANJEE, USHEER | reporter.nih.gov |
| Leveraging access to parasite natural diversity to identify Plasmodium vivax culture-adaptable strain. | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $267,168 | December 27, 2024 | November 30, 2027 | POPOVICI, JEAN | reporter.nih.gov |
| Measuring spillover effects of reactive, focal malaria elimination interventions | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $258,515 | June 10, 2019 | May 31, 2024 | BENJAMIN-CHUNG, JADE | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| University of California, San Francisco | San Francisco, CA | 32 | $52.4 million | 0 | $0 |
| Sanaria, Inc. | Rockville, MD | 20 | $39.5 million | 0 | $0 |
| Seattle Children's Hospital | Seattle, WA | 18 | $36.4 million | 0 | $0 |
| University of Washington | Seattle, WA | 12 | $27.3 million | 0 | $0 |
| Duke University | Durham, NC | 19 | $24 million | 0 | $0 |
| Harvard University D/b/a Harvard School of Public Health | Boston, MA | 21 | $22.2 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 26 | $22 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 23 | $20 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 13 | $18.9 million | 0 | $0 |
| Indiana University Indianapolis | Indianapolis, IN | 16 | $18.5 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 19 | $18 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 10 | $18 million | 0 | $0 |
| Stanford University | Stanford, CA | 11 | $16.6 million | 0 | $0 |
| University of South Florida | Tampa, FL | 16 | $16.2 million | 0 | $0 |
| Kaiser Foundation Research Institute | Oakland, CA | 2 | $14.8 million | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 10 | $14.7 million | 0 | $0 |
| Drexel University | Philadelphia, PA | 9 | $12.4 million | 0 | $0 |
| Yale University | New Haven, CT | 12 | $11.5 million | 0 | $0 |
| University of Iowa | Iowa City, IA | 12 | $11.3 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 7 | $10.4 million | 0 | $0 |
| University of Georgia Research Foundation Inc | Athens, GA | 13 | $10.1 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 4 | $9.8 million | 0 | $0 |
| Brown University | Providence, RI | 8 | $9.6 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 5 | $9.5 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 8 | $9 million | 0 | $0 |
| Case Western Reserve University | Cleveland, OH | 6 | $8.8 million | 0 | $0 |
| Portland State University | Portland, OR | 3 | $7.7 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 3 | $7.6 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 8 | $7.5 million | 0 | $0 |
| Cincinnati Childrens Hosp Med CTR | Cincinnati, OH | 2 | $7.2 million | 0 | $0 |
| The University of Central Florida Board of Trustees | Orlando, FL | 3 | $6.9 million | 0 | $0 |
| Michigan State University | East Lansing, MI | 4 | $6.9 million | 0 | $0 |
| University of New Mexico Health Scis CTR | Albuquerque, NM | 3 | $6 million | 0 | $0 |
| Children's Research Institute | Washington, DC | 2 | $5.7 million | 0 | $0 |
| University of Utah | Salt Lake City, UT | 8 | $5.6 million | 0 | $0 |
| Washington University | Saint Louis, MO | 9 | $5.4 million | 0 | $0 |
| Tulane University of Louisiana | New Orleans, LA | 2 | $5.4 million | 0 | $0 |
| Institute for Systems Biology | Seattle, WA | 2 | $5.3 million | 0 | $0 |
| Henry M. Jackson FDN for the Adv Mil/med | Bethesda, MD | 4 | $5.2 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 4 | $4.8 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 5 | $4.5 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 2 | $4.4 million | 0 | $0 |
| University of Rochester | Rochester, NY | 4 | $4.2 million | 0 | $0 |
| Boston University Medical Campus | Boston, MA | 4 | $3.9 million | 0 | $0 |
| Institut Pasteur du Cambodge | Phnom Penh | 3 | $3.8 million | 0 | $0 |
| Texas Biomedical Research Institute | San Antonio, TX | 2 | $3.7 million | 0 | $0 |
| University of Texas HLTH Science Center | San Antonio, TX | 4 | $3.7 million | 0 | $0 |
| University of Oxford | Oxford | 1 | $3.6 million | 0 | $0 |
| Pennsylvania State Univ University Park | University Park, PA | 7 | $3.6 million | 0 | $0 |
| University of California-Riverside | Riverside, CA | 4 | $3.5 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 2 | $3.5 million | 0 | $0 |
| Iowa State University | Ames, IA | 6 | $3.4 million | 0 | $0 |
| University of Vermont & ST Agric College | Burlington, VT | 1 | $3.4 million | 0 | $0 |
| Chromologic, LLC | Monrovia, CA | 3 | $3.3 million | 0 | $0 |
| Cornell University | Ithaca, NY | 1 | $3.1 million | 0 | $0 |
| Isca Technologies, Inc. | Riverside, CA | 1 | $3 million | 0 | $0 |
| Visionquest Biomedical INC | Albuquerque, NM | 2 | $3 million | 0 | $0 |
| University of Illinois at Chicago | Chicago, IL | 1 | $3 million | 0 | $0 |
| Lumen Bioscience, Inc. | Seattle, WA | 1 | $2.9 million | 0 | $0 |
| Analytical Diagnostic Solutions, Inc. | Mount Laurel, NJ | 1 | $2.9 million | 0 | $0 |
| Albert Einstein College of Medicine | Bronx, NY | 3 | $2.8 million | 0 | $0 |
| Regents of the University of Idaho | Moscow, ID | 2 | $2.6 million | 0 | $0 |
| Georgetown University | Washington, DC | 3 | $2.6 million | 0 | $0 |
| Leiden University Medical Center | Leiden | 1 | $2.6 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 3 | $2.4 million | 0 | $0 |
| Caucaseco Scientific Research Center | Cali | 2 | $2.4 million | 0 | $0 |
| Children's Hosp of Philadelphia | Philadelphia, PA | 2 | $2.4 million | 0 | $0 |
| Virginia Polytechnic Institute and State University | Blacksburg, VA | 6 | $2.4 million | 0 | $0 |
| University of California-Berkeley | Berkeley, CA | 2 | $2.3 million | 0 | $0 |
| Redbud Labs, Inc. | Durham, NC | 1 | $2.3 million | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 2 | $2.3 million | 0 | $0 |
| Univ of Sciences, Tech & Tech of Bamako | Bamako | 3 | $2.3 million | 0 | $0 |
| University of Notre Dame | Notre Dame, IN | 5 | $2.2 million | 0 | $0 |
| Makerere University College of Health Sciences | Kampala | 3 | $2.2 million | 0 | $0 |
| Northeastern University | Boston, MA | 1 | $2.1 million | 0 | $0 |
| Fred Hutchinson Cancer Center | Seattle, WA | 1 | $2.1 million | 0 | $0 |
| Vaccine Research Institute of San Diego | San Diego, CA | 1 | $2.1 million | 0 | $0 |
| Vanderbilt University | Nashville, TN | 3 | $2.1 million | 0 | $0 |
| Tufts University Boston | Boston, MA | 2 | $2 million | 0 | $0 |
| Versatope Therapeutics, Inc. | Lowell, MA | 1 | $2 million | 0 | $0 |
| Medical College of Wisconsin | Milwaukee, WI | 3 | $1.9 million | 0 | $0 |
| Morehouse School of Medicine | Atlanta, GA | 2 | $1.9 million | 0 | $0 |
| University of Arizona | Tucson, AZ | 1 | $1.9 million | 0 | $0 |
| Tmliverpool School of Tropical Medicine | Liverpool | 1 | $1.8 million | 0 | $0 |
| Cure Systems LLC | Newton Center, MA | 2 | $1.8 million | 0 | $0 |
| Colorado State University | Fort Collins, CO | 2 | $1.8 million | 0 | $0 |
| SUNY at Buffalo | Amherst, NY | 2 | $1.7 million | 0 | $0 |
| Mcgill University | Montreal | 1 | $1.7 million | 0 | $0 |
| Ohio State University | Columbus, OH | 2 | $1.7 million | 0 | $0 |
| University of Florida | Gainesville, FL | 2 | $1.7 million | 0 | $0 |
| University of Ghana | Legon | 2 | $1.6 million | 0 | $0 |
| University of Cape Town | Rondebosch | 2 | $1.6 million | 0 | $0 |
| Wadsworth Center | Menands, NY | 1 | $1.6 million | 0 | $0 |
| Hennepin Healthcare Research Institute | Minneapolis, MN | 4 | $1.6 million | 0 | $0 |
| Idaho State University | Pocatello, ID | 1 | $1.6 million | 0 | $0 |
| University of Kentucky | Lexington, KY | 1 | $1.5 million | 0 | $0 |
| Florida International University | Miami, FL | 3 | $1.5 million | 0 | $0 |
| L2 Diagnostics, LLC | New Haven, CT | 4 | $1.5 million | 0 | $0 |
| University of Nebraska Medical Center | Omaha, NE | 1 | $1.5 million | 0 | $0 |
| University of Alberta | Edmonton | 1 | $1.5 million | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 296 | $150,812,751 | 0 | $0 |
| 2024 | 310 | $154,917,984 | 0 | $0 |
| 2023 | 307 | $152,799,034 | 0 | $0 |
| 2022 | 299 | $148,863,348 | 0 | $0 |
| 2021 | 307 | $151,331,733 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Change of Recipient Organization (Type 7 Parent Clinical Trial Optional) | PA-24-254 | NIH | July 12, 2027 | Not listed | Notice number printed on 5 awards here | |
| NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed) | PA-24-194 | NIH | May 7, 2027 | Not listed | Notice number printed on 1 award here | |
| Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed) | PA-24-182 | NIH | May 8, 2027 | Not listed | Notice number printed on 1 award here | |
| Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed) | PA-24-185 | NIH | May 7, 2027 | Not listed | Notice number printed on 1 award here | |
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) | RFA-AI-27-002 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 533 awards here |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) | RFA-AI-27-005 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 533 awards here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.855 | November 16, 2026 | $50,000 | Same assistance listing 93.855 as 533 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 533 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 533 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.855 | January 7, 2027 | Not listed | Same assistance listing 93.855 as 533 awards here |
| HIV/AIDS Clinical Trials Network Leadership and Operations Centers | RFA-AI-28-001 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 533 awards here |
| HIV/AIDS Clinical Trials Network Laboratory Centers | RFA-AI-28-002 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 533 awards here |
| HIV/AIDS Clinical Trials Network Statistical and Data Management Centers | RFA-AI-28-003 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 533 awards here |
| HIV/AIDS Clinical Trials Network Clinical Trials Units | RFA-AI-28-004 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 533 awards here |
| Precision and Systems Biology to Uncover the Link Between Chronic and Infectious Diseases | RFA-AI-28-014 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 533 awards here |
| Immune Tolerance Network (UM1 Clinical Trial Required) | RFA-AI-28-005 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 533 awards here |
| Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed) | RFA-AI-28-012 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 533 awards here |
| Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) | RFA-AI-28-024 | NIH | 93.855 | February 11, 2027 | Not listed | Same assistance listing 93.855 as 533 awards here |
| NLM Institutional Grants for Research Training in Biomedical Informatics, Data Science, and AI (T15 Independent Clinical Trial Not Allowed) | RFA-LM-28-001 | NIH | 93.855 | February 11, 2027 | $775,000 | Same assistance listing 93.855 as 533 awards here |
| NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) | PA-27-100 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 533 awards here |
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.